febuxostat has been researched along with allopurinol in 487 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (allopurinol) | Trials (allopurinol) | Recent Studies (post-2010) (allopurinol) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 15,096 | 743 | 3,363 |
| Protein | Taxonomy | febuxostat (IC50) | allopurinol (IC50) |
|---|---|---|---|
| Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase | Rattus norvegicus (Norway rat) | 3.3765 | |
| Xanthine dehydrogenase/oxidase | Homo sapiens (human) | 3.1861 | |
| Xanthine dehydrogenase/oxidase | Bos taurus (cattle) | 5.0758 | |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | 8.69 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (1.03) | 18.2507 |
| 2000's | 44 (9.03) | 29.6817 |
| 2010's | 298 (61.19) | 24.3611 |
| 2020's | 140 (28.75) | 2.80 |
| Authors | Studies |
|---|---|
| B-Rao, C; Bahirat, U; Brahma, MK; Deshmukh, NJ; Dixit, A; Doshi, L; Ghosh, U; Katkar, KV; Keche, A; Khanna, S; Korde, V; Kulkarni-Almeida, A; Nemmani, KV; Shah, P; Sharma, R; Sivaramakrishnan, H; Srivastava, A | 1 |
| B-Rao, C; Bahirat, U; Bajaj, K; Brahma, MK; Burudkar, S; Damre, A; Desai, A; Deshmukh, NJ; Dixit, A; Doshi, L; Ghosh, U; Keche, A; Khanna, S; Kulkarni-Almeida, A; Nemmani, KV; Shah, P; Sharma, R; Sivaramakrishnan, H; Srivastava, A; Tannu, P | 1 |
| Ahire, Y; B-Rao, C; Bajaj, K; Burudkar, S; Damre, A; Deshmukh, NJ; Dixit, A; Ghosh, U; Keche, A; Khanna, S; Kulkarni-Almeida, A; Nemmani, KV; Shah, P; Sharma, R; Sivaramakrishnan, H; Srivastava, A; Tannu, P | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bedi, PM; Kumar, D; Nepali, K; Ojha, R; Sharma, K; Sharma, S; Singh, G | 1 |
| Chen, G; Edfeldt, F; Evenäs, J; Gränse, M; Lepistö, M; Li, C; Li, X; Liao, Y; Lundquist, B; Lv, G; Narjes, F; Rönnholm, A; Svitacheva, N; Synnergren, A; Tjörnebo, A; Varga, M; Wang, J; Wei, M; Wright, J; Yue, S | 1 |
| Cao, H; Hille, R; Pauff, JM | 1 |
| Jang, JW; Jung, SH; Kim, GT; Kim, TH; Park, H; Park, WS; Song, JU | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Anderluh, M; Jakopin, Ž; Kocić, G; Petronijević, Ž; Šmelcerović, A; Šmelcerović, Ž; Tomašič, T; Tomović, K | 1 |
| Chen, H; Li, J; Li, Z; Liu, X; Wu, F; Zhang, L; Zou, Y | 1 |
| Fu, P; Li, X; Liu, J; Ma, L | 1 |
| Bao, K; Guan, Q; Shi, A; Wang, H; Wang, S; Yang, M; Zhang, L; Zhang, W | 1 |
| Gupta, MK; Kaur, G; Mal, G; Nepali, K; S Bedi, PM; Sharma, S; Singh, A; Singh, H; Singh, JV | 1 |
| Dai, X; Liu, D; Mao, Q; Su, Y; Wang, S; Xu, G; Zhang, B | 1 |
| Bao, Z; Dai, X; Duan, Y; Mao, Q; Wang, S; Yang, Y; Zhang, B | 1 |
| Dai, X; Duan, Y; Gao, J; Lin, F; Mao, Q; Sun, M; Wang, S; Yan, C; Yang, Y; Zhang, B; Zhang, T; Zhao, J | 1 |
| Dai, R; Dai, X; Duan, Y; Gao, J; Li, J; Li, Q; Lin, F; Mao, Q; Wang, S; Yang, Y; Zhang, B; Zhang, P | 1 |
| Lin, F; Mao, Q; Sun, M; Wang, S; Zhang, B; Zhang, T; Zhao, J | 1 |
| Higashino, K; Hiroishi, K; Moriwaki, Y; Nasako, Y; Takahashi, S; Yamakita, J; Yamamoto, T | 1 |
| Couch, RC; Griffin, TB; Hasegawa, M; Horiuchi, H; Komoriya, K; Kondo, S; Osada, Y | 1 |
| Fukushima, H; Hasegawa, M; Komoriya, K; Kondo, S; Osada, Y; Takahashi, K; Tsuchimoto, M | 1 |
| Fujimura, Y; Hada, T; Higashino, K; Moriwaki, Y; Takahashi, S; Tsutsui, T; Tsutsumi, Z; Yamamoto, T | 1 |
| Horiuchi, H; Kaneko, H; Kasahara, Y; Komoriya, K; Ohta, T; Ota, M | 1 |
| Horiuchi, H; Kaneko, H; Kasahara, Y; Kobayashi, M; Komoriya, K; Kondo, S; Nishimura, S; Ota, M | 1 |
| Yamamoto, T | 1 |
| Bomalaski, JS; Clark, MA | 1 |
| Becker, MA; Hunt, B; Joseph-Ridge, N; Khosravan, R; Kisicki, J; MacDonald, P; Mulford, D; Wu, J | 1 |
| Hoshide, S; Hosoya, T; Ishikawa, T; Komoriya, K; Kubo, J; Ohno, I; Takahashi, Y; Tsuchimoto, M | 1 |
| Hoshide, S; Kamatani, N; Kobayashi, H; Komoriya, K; Kubo, J; Nakachi, T; Takeda, K; Tsuchimoto, M; Yamanaka, H | 1 |
| Becker, MA; Hase-Aoki, K; Horiuchi, H; Kasahara, Y; Kondo, S; Takano, Y; Zhao, L | 1 |
| Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Vernillet, L; Wortmann, RL | 1 |
| Schumacher, HR | 1 |
| Choy, G | 1 |
| Tomlinson, B | 1 |
| Becker, MA; Eustace, D; Joseph-Ridge, N; MacDonald, PA; Palo, WA; Schumacher, HR; Streit, J; Wortmann, RL | 1 |
| Moreland, LW | 1 |
| Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Mayer, MD; Vernillet, L; Wu, JT | 1 |
| Chen, LX; Schumacher, HR | 1 |
| Lustberg, ME | 1 |
| Gelber, AC | 1 |
| Grabowski, BA; Joseph-Ridge, N; Khosravan, R; Vernillet, L; Wu, JT | 1 |
| Lee, SJ; Terkeltaub, RA | 1 |
| Ziegler, R | 1 |
| Bache, RJ; Chen, Y; Hou, M; Hu, Q; Zhang, J; Zhao, L | 1 |
| Bruce, SP | 1 |
| Hershfield, MS; Sundy, JS | 1 |
| Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Zhao, L | 1 |
| Hamlin, RL; Kijtawornrat, A; Lolly, JL; Roche, BM; Shemanski, D; Wessale, JL; Zhao, L | 1 |
| Avila-Casado, C; Bautista-García, P; Franco, M; Johnson, RJ; Nakagawa, T; Sánchez-Lozada, LG; Soto, V; Tapia, E; Vega-Campos, IP; Zhao, L | 1 |
| Nishino, T; Okamoto, K | 1 |
| Okamoto, K | 1 |
| Hoshide, S; Kanou, M; Mukoyoshi, M; Muroga, H; Nishimura, S; Taniguchi, K; Umeda, S | 1 |
| Becker, MA; Hunt, BJ; Joseph-Ridge, N; Lademacher, C; MacDonald, PA | 1 |
| Joseph-Ridge, N; Khosravan, R; Kukulka, MJ; Vernillet, L; Wu, JT | 1 |
| Sundy, JS | 2 |
| Becker, MA; Hunt, B; Joseph-Ridge, N; Lademacher, C; Macdonald, PA; Schumacher, HR; Streit, J; Wortmann, RL | 1 |
| Yu, KH | 1 |
| Kirkpatrick, P; Pascual, E; Sivera, F; Yasothan, U | 1 |
| Becker, MA; Lademacher, C; Lloyd, E; MacDonald, PA; Schumacher, HR | 1 |
| Traynor, K | 1 |
| Becker, MA; Chohan, S | 1 |
| Edwards, NL | 1 |
| Pandor, A; Stevenson, M | 1 |
| Hall, HA; Poon, SH; Zimmermann, B | 1 |
| Ernst, ME; Fravel, MA | 1 |
| Jansen, TL; Reinders, MK | 1 |
| Grabowski, BA; Khosravan, R; Mulford, DJ; Vernillet, L | 1 |
| Becker, MA; Espinoza, LR; Lademacher, C; Lloyd, E; MacDonald, P; Schumacher, HR; Wells, AF | 1 |
| Bardin, T; Barskova, V; Doherty, M; Guerne, PA; Jansen, TL; Leeb, B; Pascual, E; Perez-Ruiz, F; Pimentão, J; Punzi, L; Richette, P; Tausche, AK; Uhlig, T; Zimmermann-Górska, I | 1 |
| Barrons, R; Love, BL; Snider, KM; Veverka, A | 1 |
| Bache, R; Chen, Y; Hu, X; Wessale, J; Xu, X; Zhang, P; Zhao, L | 1 |
| Julkunen, H; Konttinen, YT | 1 |
| Grabowski, B; Khosravan, R; Lademacher, C; Vernillet, L; Wu, JT | 1 |
| Burns, CM; Wortmann, RL | 1 |
| Singh, JA | 7 |
| Gao, LG; Hui, RT; Luo, F; Wen, D; Yao, XP; Zhang, L; Zhou, XL | 1 |
| Quillen, DM | 1 |
| Graser, E; Pope, RS; Zychowicz, ME | 1 |
| El-Zawawy, H; Mandell, BF | 1 |
| Cohen, MG | 1 |
| Gray, CL; Walters-Smith, NE | 1 |
| Hunt, B; Jackson, RL; Macdonald, PA; Wortmann, RL | 1 |
| Dubost, JJ; Mathieu, S; Soubrier, M | 1 |
| Freeman, BA; Hundley, NJ; Kelley, EE; Malik, UZ; Radi, R; Romero, G; Tarpey, MM | 1 |
| Doghramji, PP | 1 |
| Goldfarb, DS; Gunawardhana, L; Hunt, B; MacDonald, PA | 1 |
| Hu, Q; Kamdar, F; Lee, J; Mansoor, A; Zhang, J | 1 |
| El-Armouche, A; Emons, J; Wittköpper, K | 1 |
| Reid, G; Uh, M | 1 |
| Hosoya, T; Kamatani, N; Naoyuki, K; Tatsuo, H | 1 |
| Fujimori, S; Hada, T; Hosoya, T; Kamatani, N; Kohri, K; Matsuzawa, Y; Nakamura, T; Ueda, T; Yamamoto, T; Yamanaka, H | 2 |
| Fujimori, S; Hada, T; Hisashi, Y; Hosoya, T; Kamatani, N; Kenjiro, K; Kohri, K; Matsuzawa, Y; Nakamura, T; Naoyuki, K; Shin, F; Takanori, U; Tatsuo, H; Tetsuya, Y; Toshikazu, H; Toshitaka, N; Ueda, T; Yamamoto, T; Yamanaka, H; Yuji, M | 3 |
| Hosoya, T; Iwao, O; Ohno, I; Tatsuo, H | 1 |
| Bardin, T; Ottaviani, S; Richette, P | 1 |
| Chohan, S | 1 |
| Kriegsmann, J; Lange, U; Müller-Ladner, U; Panzner, I; Tausche, AK | 1 |
| Becker, MA; Chefo, S; Chohan, S; Jackson, RL; MacDonald, PA | 1 |
| Schmidt, BM; Wagner, AD | 1 |
| Becker, MA; Gunawardhana, L; Hunt, B; MacDonald, PA | 1 |
| Das, P; Suresh, E | 1 |
| Chefo, S; Jackson, RL; MacDonald, PA; Wells, AF | 1 |
| Jutkowitz, E; Meltzer, M; Pizzi, LT | 1 |
| Inoue, K; Isaka, Y; Kaimori, J; Kawada, N; Matsui, I; Moriyama, T; Omori, H; Rakugi, H; Takabatake, Y; Ueda, Y; Yamamoto, R | 1 |
| Hunt, B; Jackson, RL; MacDonald, PA | 1 |
| Gunawardhana, L; Naik, H; Tsai, M; Wu, JT | 1 |
| Curiel, RV; Guzman, NJ | 1 |
| Asmahan, MI; Hilmi, BA; Rosman, A | 1 |
| Richette, P | 1 |
| Manger, B | 1 |
| Chohan, S; Dabholkar, A; Hunt, B; Jackson, R; White, WB | 1 |
| Doghramji, PP; Mandell, BF; Pope, RS | 1 |
| Carey, JJ; Conway, R; Coughlan, RJ | 1 |
| Ding, L; Huang, NY; Huang, Y; Lin, YF; Liu, RJ; Liu, XX; Wang, SL; Xiao, HF; Yang, J | 1 |
| Isaka, Y; Kaimori, JY; Kawada, N; Kitamura, H; Moriyama, T; Rakugi, H; Takahara, S; Tsuda, H | 1 |
| Shafik, AN | 1 |
| Butani, L; Calogiuri, G; Di Leo, E; Ferrannini, A; Foti, C; Nettis, E | 1 |
| Keenan, RT | 1 |
| Lopez-Olivo, MA; Suarez-Almazor, ME; Tayar, JH | 1 |
| Alonso-Pacho, A; de la Puerta González-Quevedo, C; Fabregate-Fuente, M; Sabán-Ruiz, J | 1 |
| Chen, S; Cheng, Q; Li, Q; Liu, L; Luo, T; Lv, Q; Mei, M; Yang, S; Ye, P; Zhang, W | 1 |
| Chefo, S; Gunawardhana, L; MacDonald, PA; Whelton, A | 1 |
| Burnett, RJ; Davis, RP; Fink, GD; Garver, HS; Szasz, T; Watts, SW | 1 |
| Bianchi, G; Borghi, C; Bortoluzzi, A; Cimmino, MA; D'Avola, GM; Desideri, G; Di Giacinto, G; Favero, M; Govoni, M; Grassi, W; Lombardi, A; Manara, M; Marangella, M; Matucci Cerinic, M; Medea, G; Minisola, G; Prevete, I; Punzi, L; Ramonda, R; Scirè, CA; Spadaro, A | 1 |
| Hata, H; Hata, M; Nakata, K; Sezai, A; Shiono, M; Soma, M; Wakui, S; Yoshitake, I | 1 |
| Becker, MA; Hunt, BJ; Jackson, RL; MacDonald, PA | 1 |
| Inamadugu, JK; Katreddi, HR; Pilli, NR; Ramesh, M; Vaka, VR | 1 |
| Franklin, JM; Kim, SC; Liu, J; Schmidt, BM; Schneeweiss, S; Solomon, DH | 1 |
| Hu, XJ; Liu, J; ShenTu, JZ; Shi, Z | 1 |
| Chefo, S; Goldfarb, DS; Gunawardhana, L; MacDonald, PA; McLean, L | 1 |
| Fujimura, H; Honorat, JA; Kinoshita, M; Koda, T; Mochizuki, H; Nakatsuji, Y; Okuno, T; Sakoda, S; Shirakura, T; Tada, S; Takata, K | 1 |
| Aringer, M; Bielitz, C; Christoph, M; Forkmann, M; Kopprasch, S; Richter, U; Tausche, AK; Wunderlich, C | 1 |
| Busso, N; Ives, A; Nomura, J; So, A; Tamura, M; Tsujimoto, S; Yamanaka, Y | 1 |
| Murasawa, T; Ohno, D; Otsuka, T; Sakai, Y; Sato, N; Tsuruoka, S | 1 |
| Bakris, GL; Doghramji, PP; Keenan, RT; Silber, SH | 1 |
| Ehteshami-Afshar, A; Faruque, LI; Homik, J; Tjosvold, L; Tonelli, M; Wiebe, N | 1 |
| Berns, JS; Wilson, FP | 1 |
| Stamp, LK | 2 |
| Bao, C; Du, H; Gu, J; Huang, A; Huang, X; Jiang, L; Li, J; Li, X; Li, Z; Liu, Y; Zhang, Y; Zhang, Z; Zhao, D; Zhu, P; Zuo, X | 1 |
| Bégin, J; Doré, M; Frenette, AJ; Mansour, AM; Troyanov, Y | 1 |
| Hara, T; Hayashida, Y; Inui, M; Kakehi, Y; Kohno, M; Moriwaki, K; Nishijima, Y; Nishiyama, A; Sofue, T; Ueda, N | 1 |
| Aoki, T; Hishida, M; Maekawa, M; Morinaga, T; Tamai, H; Tomida, H | 1 |
| Fuchinoue, S; Nakajima, I; Teraoka, S; Tojimbara, T; Yashima, J | 1 |
| Espinoza, LR; Grewal, HK; Martinez, JR | 1 |
| Akhras, KS; Hatoum, H; Khanna, D; Khanna, P; Lin, SJ; Shiozawa, A | 1 |
| Busso, N; Ives, A; Kobayashi, T; Matsui, C; Nomura, J; Shirakura, T; So, A; Tamura, M; Tsujimoto, S; Yamanaka, Y | 1 |
| Arowojolu, O; Goldfarb, DS | 1 |
| Bocale, R; Desideri, G; Ferri, C; Grassi, D; Pontremoli, R | 1 |
| Becker, MA; Chaichian, Y; Chohan, S | 1 |
| Banse, C; Fardellone, P; Paccou, J | 1 |
| Bardelli, M; Cantarini, L; Galeazzi, M; Rigante, D; Vitale, A | 1 |
| Joo, H; Joo, K; Jung, KH; Kwon, SR; Lim, MJ; Park, W | 1 |
| Chen, J; Fu, Y; Li, P; Mo, HY; Song, HP; Zhang, H; Zhang, M | 1 |
| Ohya, M; Shigematsu, T | 1 |
| Mounsey, A; Tillett, J; White, S | 1 |
| De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; Jennings, CG; MacDonald, TM; Mackenzie, IS; McMurray, J; Nuki, G; Perez Ruiz, F; Ralston, S; Walters, M; Webster, J | 1 |
| Ihm, CG; Jeong, KH; Kim, YG; Lee, HJ; Lee, SH; Lee, TW; Moon, JY; Sung, JY | 1 |
| Itabashi, M; Mochizuki, T; Moriyama, T; Nitta, K; Takei, T; Tsuchiya, K; Tsuruta, Y | 1 |
| Kim, HA; Seo, YI; Song, YW | 1 |
| Brucato, AL; Corrao, S; Di Corato, P; Djade, CD; Franchi, C; Ghidoni, S; Mannucci, PM; Marcucci, M; Marengoni, A; Nobili, A; Pasina, L; Salerno, F; Tettamanti, M | 1 |
| Bombardier, C; Buchbinder, R; Edwards, CJ; Kydd, AS; Seth, R | 1 |
| Choi, HK; Jutkowitz, E; Kuntz, KM; Pizzi, LT | 1 |
| Bennett, K; McGowan, B; Silke, C; Whelan, B | 1 |
| Kataoka, H; Rock, KL; Yang, K | 1 |
| Iwasaki, H; Kishi, S; Matsuda, Y; Nakamura, T; Ookura, M; Tai, K; Takai, M; Ueda, T; Yamauchi, T; Yoshida, A | 1 |
| Dalbeth, N; Robinson, PC | 1 |
| Bridgeman, MB; Chavez, B | 1 |
| Bottorff, MB; Gandhi, PK; Gentry, WM; Ma, Q | 1 |
| Hata, H; Ishii, Y; Nakata, K; Osaka, S; Sezai, A; Shiono, M; Soma, M; Yaoita, H | 1 |
| Asahi, K; Hayashi, Y; Kanno, M; Kimura, H; Nakayama, M; Tanaka, K; Tani, Y; Terawaki, H; Watanabe, K; Watanabe, T | 1 |
| Flipo, RN; Patrikos, DK; Richette, P | 1 |
| Abe, Y; Fukui, T; Maruyama, M; Yamauchi, K; Yasuda, T; Yoshitaka, S | 1 |
| Li, L; Lu, W; Sun, Y; Zhou, TY | 1 |
| Chang, JY; Chin, SW; Chu, MT; Chung, WH; Huang, YL; Hung, SI; Pan, RY; Wang, WC | 1 |
| Akhras, KS; Shiozawa, A; Singh, JA | 1 |
| Kim, KA; Park, JY | 1 |
| Asano, T; Fujishiro, M; Fukushima, T; Kamata, H; Kanaoka, R; Katasako, A; Kushiyama, A; Matsunaga, Y; Mori, K; Nakatsu, Y; Sakoda, H; Seno, Y; Yamamotoya, T | 1 |
| Chen, S; Ji, H; Ji, Q; Lin, J; Liu, B; Liu, H; Liu, P; Liu, X; Lu, Y; Ming, J; Peng, Y; Wang, J; Wang, Y; Xu, S; Zhang, Y | 1 |
| Arava, S; Arya, DS; Bharti, S; Bhatia, J; Golechha, M; Krishnamurthy, B; Nag, TC; Rani, N; Ray, R | 1 |
| Dalbeth, N; Stamp, LK | 1 |
| Nishizawa, T; Nomura, S; Taniura, T | 1 |
| Bansal, AK; Jagia, M; Patel, J; Patel, S | 1 |
| Aurer, I; Baldini, S; Borsaru, G; Bosi, A; Capriati, A; Federico, M; Glushko, NL; Grosicki, S; Jakucs, J; Jordan, K; Maggi, CA; Mayer, J; Montesinos, P; Nagy, Z; Pristupa, AS; Rego, EM; Ribera, JM; Ristic, D; Scartoni, S; Simonelli, C; Spina, M | 1 |
| Aniel-Quiroga, MA; Atxotegi, J; Chinchilla, SP; Herrero-Beites, AM; Perez-Ruiz, F; Urionagüena, I | 1 |
| Hirayama, A; Nagao, K; Tani, S | 1 |
| Gahn, JC; Mitri, G; Shiozawa, A; Smolen, LJ | 2 |
| Altan, A; Bancroft, T; Shiozawa, A; Singh, JA | 1 |
| Bardin, T; Chalès, G; Clerson, P; Delayen, A; Flipo, RM; Korng Ea, H; Pascart, T; Roujeau, JC | 1 |
| Fahmi, AN; Salem, HA; Shebl, AM; Shehatou, GS | 2 |
| Chen, CJ; Chen, DY; Hsu, PN; Lai, JH; Lin, HY; Yu, KH | 1 |
| Reuss-Borst, MA | 1 |
| Carcedo, D; Díaz-Torné, C; Perez-Ruiz, F | 1 |
| Füeßl, HS; Stiefelhagen, P | 1 |
| Bäurle, A | 1 |
| Borghi, C; Perez-Ruiz, F | 1 |
| Fujimaki, K; Fujisaki, T; Gemba, K; Goto, T; Kaneko, M; Kawai, Y; Kiguchi, T; Kirito, K; Maemondo, M; Nakajima, A; Okamoto, M; Takeda, K; Tamura, K; Ueda, T | 1 |
| Mitri, G; Schulman, KL; Tidwell, BA; Turpin, RS; Wittbrodt, ET | 1 |
| Higa, A; Iseki, K; Ishida, A; Kohagura, K; Nagahama, K; Ohya, Y; Sakima, A; Tana, T; Yamazato, M | 1 |
| Chang, NC; Lee, TM; Lin, SZ | 1 |
| Kobayashi, T; Masuzaki, H; Matsui, C; Nomura, J; Shirakura, T; Tamura, M | 1 |
| Bakinde, N; Mome, R | 1 |
| Michel, MC; Steubl, D | 1 |
| Komers, R; Oyama, TT; Schneider, J; Xu, B | 1 |
| Echizen, H; Hirai, T; Kimura, T | 1 |
| Andrés, M; Gil, S; Pascual, E; Quilis, N; Ranieri, L; Vela, P | 1 |
| Ako, J; Bando, YK; Eguchi, K; Higashi, Y; Inoue, T; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kuroyanagi, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H | 1 |
| Flynn, RW; MacDonald, TM; Mackenzie, IS; McDonnell, P; Rogers, A | 1 |
| Christensen, HD; Hansen, IM; Morillon, MB; Sheta, HM | 1 |
| Chen, C; Lü, JM; Yao, Q | 1 |
| Hildebrand, BA; Jaster, P; Westgate, J | 1 |
| Dalbeth, N; Stamp, L | 1 |
| Agrawal, A; Saigal, R | 1 |
| Lien, YH; Logan, JL | 1 |
| Day, RO; Graham, GG; Kamel, B; Kannangara, DR; Williams, KM | 1 |
| Carroll, MB; Shaak, TL; Smith, DM | 1 |
| Chen, F; Deng, L; Li, Y; Lin, K; Shi, X; Wang, Y; Zhaoliang, S | 1 |
| Bryant, CL; Fourakre, TN; Hughes, JC; Salvig, BE; Stone, WJ; Wallace, JL | 1 |
| Chen, X; Su, J; Tian, J; Zhou, Q; Zhou, T; Zhu, J | 1 |
| Aviña-Zubieta, JA; Choi, HK; De Vera, MA; McCormick, N; Rai, SK; Sayre, EC; Shojania, K | 1 |
| Corbett, EJM; McGill, NW; Pentony, P | 1 |
| Hoshi, H; Kazama, JJ; Terawaki, H | 1 |
| Pope, JE; Zhang, T | 1 |
| Deeks, ED | 1 |
| Chen, H; Jiang, L; Kong, X; Ma, L; Sun, Y; Zhang, X; Zhang, Z; Zhou, J; Zhou, Y | 1 |
| Hayashi, M; Kikuchi, R; Matsushita, T; Murohara, T; Nakamura, S; Nakayama, T; Niwa, T; Shoaib Hamrah, M; Takeshita, K; Uchida, Y; Wu Cheng, X; Wu, H; Yamamoto, K; Yisireyili, M | 1 |
| Neogi, T; Vargas-Santos, AB | 1 |
| Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M; Uzu, T | 1 |
| Alshahawey, M; Elsaid, TW; Sabri, NA; Shahin, SM | 1 |
| Infante, J; Lage-Martínez, C; Paredes, MJ; Pérez-Pereda, S | 1 |
| Cleveland, JD; Singh, JA | 7 |
| Alarid-Escudero, F; Choi, HK; Jalal, H; Jutkowitz, E; Kuntz, KM | 1 |
| Kim, JW; Kwak, SG; Park, SH | 1 |
| Hill-McManus, D; Hughes, D; Lane, S; Marshall, S; Soto, E | 2 |
| Britnell, SR; Brown, JN; Chillari, KA | 1 |
| Hori, D; Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D | 1 |
| Cimmino, MA; Cutolo, M; Perez-Ruiz, F | 1 |
| Ishii, T; Oyama, K; Taguri, M; Tamura, K | 1 |
| Borghi, C; Bove, M; Cicero, AFG | 1 |
| Bolignano, D; Buemi, M; Cernaro, V; D'Arrigo, G; Gembillo, G; Pisano, A | 1 |
| Feig, DI; Gunawardhana, L; Hunt, B; McLean, L; Palmer, RN; Punzi, HA; Whelton, A | 1 |
| Honorat, JA; Kinoshita, M; Koda, T; Kumanogoh, A; Mochizuki, H; Nakatsuji, Y; Namba, A; Okuno, T; Sakaguchi, M; Sakoda, S; Sanda, E; Sasaki, T; Shimizu, M; Shirakura, T; Sumi-Akamaru, H; Takata, K; Tamura, M; Yamashita, K | 1 |
| Milanovic, I; Nigovic, B | 1 |
| Chiu, HT; Chou, HW; Huang, HC; Kuo, CC; Ting, IW; Tsai, CW; Yeh, HC | 1 |
| Edvardsson, VO; Eiriksson, F; Goldfarb, DS; Oddsdottir, GS; Palsson, R; Runolfsdottir, HL; Sch Agustsdottir, IM; Thorsteinsdottir, M; Thorsteinsdottir, UA | 1 |
| Baek, CH; Han, DJ; Kim, H; Park, SK; Yang, WS | 1 |
| Balia, F; Borrelli, S; De Nicola, L; De Stefano, T; Garofalo, C; Minutolo, R; Nettuno, F; Pacilio, M; Sagliocchi, A; Scarpati, L; Sguazzo, A; Vinci, G; Vita, C | 1 |
| Treviño-Becerra, A | 1 |
| Chang, WX; Kumagai, T; Shibata, S; Tamura, Y; Uchida, S | 1 |
| Madero, M; Ramirez-Sandoval, JC | 1 |
| Breton, E; Czarny, M; Gerstenblith, G; Hays, AG; Iantorno, M; Lai, S; Palmer, RN; Schär, M; Weiss, RG; Whelton, A | 1 |
| Aksenov, S; Eriksson, UG; Peck, CC; Stanski, DR | 1 |
| Becker, MA; Borer, JS; Castillo, M; Gorelick, PB; Gunawardhana, L; Hunt, B; Saag, KG; Whelton, A; White, WB | 2 |
| Kuehn, BM | 1 |
| Lioté, F; Pascart, T | 1 |
| Basile, M; Cicchetti, A; Drago, C; Rolli, FR; Ruggeri, M | 1 |
| Brittan, K; Brophy, M; Davis-Karim, A; Henrie, AM; Mikuls, TR; Neogi, T; Newcomb, J; O'Dell, JR; Palevsky, PM; Pillinger, MH; Pittman, D; Taylor, TH; Timilsina, S; Wu, H | 1 |
| Cheng, H; Liu, J; Liu, W; Yan, D; Zhang, Y; Zuo, X | 1 |
| Fujigaki, Y; Goto, D; Kato, A; Ohashi, N; Ohishi, K; Sato, T; Takeda, A; Tsuji, T; Yasuda, H | 1 |
| McHugh, J | 1 |
| Janssen, CA; Krol, M; Oude Voshaar, MAH; van de Laar, MAFJ; Vonkeman, HE | 1 |
| Cho, YS; Han, N; Kim, YS; Kwak, CH; Oh, JM; Sohn, M | 1 |
| Choi, H; Dalbeth, N; Neogi, T; Stamp, L; Terkeltaub, R | 3 |
| Echizen, H; Hirai, T; Itoh, T; Kimura, T | 1 |
| Tian, JY; Xiao, ZY; Yan, DA; Ye, F; Zhang, L | 1 |
| Desai, RJ; Kang, EH; Kim, SC; Liu, J; Neogi, T; Solomon, DH; Zhang, M | 1 |
| Baunthiyal, M; Gupta, A; Pathak, RK; Shukla, R | 1 |
| Ako, J; Fukaya, H; Igarashi, T; Kishihara, J; Murakami, M; Nakamura, H; Niwano, H; Niwano, S; Oikawa, J; Satoh, A; Tamaki, H; Yoshizawa, T | 1 |
| Müller-Wieland, D; Nitschmann, S | 1 |
| Cheetham, TC; Levy, G; Rashid, N; Shi, JM | 1 |
| Wang, S | 1 |
| Jansen, TL; Perez-Ruiz, F; Richette, P; Tausche, AK | 1 |
| Ito, O; Kohzuki, M; Kurosawa, R; Miura, T; Nakamura, T; Namai-Takahashi, A; Sakuyama, A; Takahashi, J | 1 |
| Li, C; Wu, X | 1 |
| Kuwabara, M | 2 |
| Butt, NF; Iqbal, A; Lal, B; Randhawa, FA; Rathore, R; Waseem, T | 1 |
| Chuma, M; Fujino, H; Fukushima, K; Goda, M; Horinouchi, Y; Ikeda, Y; Ikuto, R; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Kondo, M; Murai, Y; Takechi, K; Tsuchiya, K; Zamami, Y | 1 |
| White, WB | 1 |
| Bettiol, A; Crescioli, G; Cricelli, C; Lapi, F; Lombardi, N; Marconi, E; Medea, G; Parretti, L; Vannacci, A | 1 |
| Amaral, JH; Castro, MM; Conde-Tella, SO; Gerlach, RF; Guimarães, DA; Pinheiro, LC; Rizzi, E; Tanus-Santos, JE | 1 |
| Robinson, PC | 1 |
| Hong, S; Kim, YG; Kwon, OC; Lee, CK; Lee, JS; Lee, SS; Oh, JS; Won, J; Yoo, B | 1 |
| Fields, TR | 1 |
| Jansen, TLTA; Janssen, M | 1 |
| Asano, T; Fujishiro, M; Inoue, MK; Inoue, Y; Kushiyama, A; Masaki, T; Matsunaga, Y; Morii, K; Nakatsu, Y; Ono, H; Sakoda, H; Sasaki, K; Suzuki, Y; Ueda, K; Yamamotoya, T | 1 |
| Cicalese, S; Eguchi, S; Scalia, R | 1 |
| Chae, DW; Cho, HS; Cho, YJ; Hwang, JH; Jee, YK; Jeong, YY; Jun, JB; Jung, HY; Jung, JW; Kang, MG; Kim, DK; Kim, GH; Kim, HY; Kim, JY; Kim, MH; Kim, S; Kim, SH; Kim, SJ; Kim, SM; Kwon, SK; Lee, EK; Lee, JM; Lee, JP; Oh, YK; Park, HW; Park, JS; Ryu, DR; Shin, J; Yang, MS | 1 |
| Chen, P; Chen, X; Fu, Q; Gao, X; Li, J; Liu, L; Shen, X; Wang, C | 1 |
| Lee, JW; Lee, KH | 1 |
| Amin, OA; Bakry, R; El-Kimary, EI; El-Yazbi, FA; Khamis, EF; Younis, SE | 1 |
| Chen-Xu, M; Choi, HK; Pillinger, MH; Rai, SK; Yokose, C | 1 |
| Chen, Y; Deng, L; Li, Z; Liu, Y; Nie, L; Xie, R; Xu, X | 1 |
| Abeles, AM; Pillinger, MH | 1 |
| Chao, PH; Chen, WW; Hsiao, FY; Huang, WI; Lin, CW | 1 |
| Chang, CJ; Chang, YC; Chen, CB; Chen, CH; Chen, SM; Chen, WT; Chi, CC; Chung, WH; Hsu, LA; Hung, SI; Lin, KM; Lin, YJ; Lu, CW; Pan, RY; Su, SC; Wang, CW; Wu, YJ; Yu, KH | 1 |
| Flynn, RWV; MacDonald, TM; Mackenzie, IS; Rogers, A | 1 |
| Ahmed, AAE; Ahmed, MAE; El Morsy, EM | 1 |
| Ferdaus, MZ; Fujikawa, K; Nabika, T; Ngarashi, D; Ohara, H; Zahid, HM | 1 |
| Borghi, C; Cicero, AFG; Cosentino, ER; Degli Esposti, D; Kuwabara, M | 1 |
| Gupta, MK; Singh, JA | 1 |
| Borghi, C; Mancia, G; Narkiewicz, K | 1 |
| Ješina, P; Pavelcova, K; Pavelka, K; Pavlikova, M; Stiburkova, B | 1 |
| Masi, S; Pugliese, NR; Taddei, S | 1 |
| Kim, JM; Kim, SH; Lee, SY; Son, CN | 1 |
| Bellos, I; Kontzoglou, K; Pergialiotis, V; Psyrri, A | 1 |
| Hill-McManus, D; Hughes, DA; Marshall, S; Soto, E | 1 |
| Bubb, MR | 1 |
| Citoni, B; Presta, V; Tocci, G | 1 |
| Choi, HK; Kang, EH; Kim, SC; Lee, EB; Lee, YJ; Shin, A; Song, YW | 1 |
| Hisaka, A; Kurebayashi, N; Miyano, K; Nonaka, M; Sakurai, T; Sato, H; Uezono, Y; Uzu, M; Yanagihara, K | 1 |
| Adusumalli, S; Akhlaghi, F; Jamwal, R; Leggio, L; Obach, RS; Ryder, TF | 1 |
| Li, Y; Liu, M; Lu, Y; Meng, J; Zhang, X | 1 |
| Mankad, R | 1 |
| Hsieh, SC; Lin, FJ; Lin, LY; Shen, LJ; Su, CY | 1 |
| Deng, JX; Jie, LG; Qu, Y; Wu, J; Yu, QH; Zhang, YP | 1 |
| Kang, EH; Kim, SC | 1 |
| Araujo, E; Baraf, HSB; Bayat, S; Cavallaro, A; Ellmann, H; Kleyer, A; Lell, M; Manger, B; Rech, J; Schenker, H; Schett, G; Simon, D; Tascilar, K | 1 |
| Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML | 1 |
| Johnson, TA; Kamatani, N; Kuwabara, M | 1 |
| Oyagüez, I; Pérez-Ruiz, F; Presa, M | 1 |
| Hisatome, I; Kondoh, H; Matsumura, Y; Ohtahara, A; Takeda, T; Teramoto, K | 1 |
| Amirshahrokhi, K | 1 |
| Bechman, K; Galloway, JB; Lanyon, P; Russell, MD; Rutherford, AI; Subesinghe, S; Yates, M | 1 |
| Chen, JS; Chiou, MJ; Chung, TT; Hsieh, AH; Kuo, CF; Lan, WC; Luo, SF; Tseng, WY; Wang, LC; Yu, KH | 1 |
| Asano, T; Fujishiro, M; Inoue, MK; Kikuchi, T; Kushiyama, A; Masaki, T; Matsunaga, Y; Mizuno, Y; Morii, K; Nakatsu, Y; Ono, H; Sakoda, H; Sasaki, K; Takahashi, M; Ueda, K; Yamamotoya, T | 1 |
| Anderson, GF; Chang, SH; Chen, YC; Hsiao, CY; Hsu, YO; Huang, YT; Hung, CC; Kuo, CF; Kuo, G; Lee, CC; Lin, CY; Lin, HL; Lin, WT; Tian, YC; Tsai, CY; Wu, CY; Wu, IW; Yang, CC; Yang, CW; Yang, HY; Yen, TH | 1 |
| Abdel-Gaber, SA; Abdelzaher, WY; El-Sheikh, AA; Gad, AA | 1 |
| Peng, Q; Wan, D; Wang, X; Yang, G; Zhang, X | 1 |
| Abu-Risha, SE; Amer, MS; El-Mahdy, NA; Saleh, DA | 1 |
| Yang, AY | 1 |
| Baek, CH; Chang, JW; Kim, H; Lee, SK; Yang, WS | 1 |
| Batteux, B; Gras-Champel, V; Laville, SM; Liabeuf, S; Marienne, J; Masmoudi, K; Rey, A | 1 |
| Fujii, K; Hagiwara, A; Hayakawa, N; Hishiki, T; Inoue, H; Itoh, H; Kabe, Y; Kubo, A; Miyashita, K; Ryuzaki, M; Sato, M; Suematsu, M; Tamaki, M | 1 |
| Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S | 1 |
| Ahn, SM; Ghang, B; Kim, J; Kim, YG; Lee, CK; Yoo, B | 1 |
| Chaumont, M; Coremans, C; Cullus, P; De Becker, B; Delporte, C; Franck, T; Rousseau, A; Van Antwerpen, P; van de Borne, P; Zouaoui Boudjeltia, K | 1 |
| Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG | 1 |
| Abhishek, A | 1 |
| Asad, A; Batra, S; Ochani, RK; Yasmin, F | 1 |
| Cheung, BMY; Ho, J; Hung, JKF; Ju, C; Lai, JCL; Lai, RWC; Li, KHC; Liu, T; Liu, Y; Tam, LS; Tse, G; Tsoi, MF; Wong, ICK | 1 |
| Hoshide, S; Kabutoya, T; Kario, K; Ueno, H | 1 |
| Agustsdottir, IMS; Dao, M; Edvardsson, VO; Indridason, OS; Knebelmann, B; Li, J; Milliner, DS; Palsson, R; Runolfsdottir, HL | 1 |
| Chen, G; Honda, M; Kaneko, S; Matsui, C; Mizukoshi, E; Nagashimada, M; Nagata, N; Ni, Y; Nishikawa, T; Ota, T; Sakai, Y; Shimakami, T; Shirakura, T; Xu, L; Yamashita, T; Zhuge, F | 1 |
| Azar, A; Koenig, D; Royer, C | 1 |
| Afsar, B; Cherney, D; Covic, A; Dincer, N; Erden, N; Kanbay, M; Kuwabara, M; Ortiz, A; Rossignol, P; Sag, AA; Siriopol, D; Yilmaz, O | 1 |
| Choi, SW; Choi, SY; Lee, S; Lim, DH; Oh, JS; So, MW | 1 |
| Bayoumi, A; Fadl, RR; Gayyed, MF; Ibrahim, S; Ibrahim, YF; Refaie, M | 1 |
| Cao, L; Wan, WG; Xue, Y; Yang, X; Zhao, L; Zhao, TY; Zhu, XX; Zou, HJ | 1 |
| Alten, R; Mischkewitz, M; Nitschmann, S | 1 |
| Borghi, C; Johnson, RJ; Kuwabara, M | 1 |
| Abdel-Aziz, AM; Baky, MAE; Hassan, OA; Mohamed, MZ; Mohammed, HH | 1 |
| Hao, Z; Jie, S; Ke, L; Wentao, H; Xiaokang, L; Yunhua, M | 1 |
| Hirose, T; Ito, O; Kohzuki, M; Mori, T; Nakamura, T; Ohsaki, Y; Rong, R; Takahashi, K; Totsune, K; Yamakoshi, S | 1 |
| Abeles, AM; Bae, SS; Brignardello-Petersen, R; Dalbeth, N; Danve, A; FitzGerald, JD; Gelber, AC; Guyatt, G; Harrold, LR; Khanna, D; Khanna, PP; Kim, SC; King, C; Lenert, A; Levy, G; Libbey, C; Mikuls, T; Mount, D; Neogi, T; Pillinger, MH; Poon, S; Qasim, A; Rosenthal, A; Sehra, ST; Sharma, TSK; Sims, JE; Singh, JA; Smith, BJ; Toprover, M; Turgunbaev, M; Turner, AS; Wenger, NS; Zeng, L; Zhang, MA | 1 |
| Anzai, T; Fukushima, A; Furihata, T; Higashikawa, K; Kakutani, N; Katayama, T; Kinugawa, S; Kuge, Y; Maekawa, S; Matsumoto, J; Nakajima, T; Nakano, I; Nambu, H; Nio-Kobayashi, J; Obata, Y; Sabe, H; Saito, A; Shirakawa, R; Takada, S; Tsuda, M; Yamanashi, K; Yasui, H; Yokota, T | 1 |
| Lin, CJ; Lin, JY; Shi, Y; Sun, SS; Zhang, DH | 1 |
| Brown, JN; Hu, AM | 1 |
| Backman, JT; Deng, F; Jaatinen, T; Keskitalo, JE; Lapatto-Reiniluoto, O; Lehtisalo, M; Neuvonen, M; Niemi, M; Tornio, A; Viinamäki, J | 1 |
| Ahn, E; Kim, A; Kim, GT; Kim, Y; Lee, SG; So, MW | 1 |
| Andraca-Carrera, E; Hsueh, YH; Mistry, K; Neuner, R; Nikolov, NP; Seymour, S | 1 |
| Hayama, Y; Kuribayashi-Okuma, E; Morimoto, C; Omizo, H; Shibata, S; Tamura, Y; Uchida, S; Ueno, M | 1 |
| Hsu, PK; Lee, YH; Wei, JCC | 1 |
| Chung, WH; Ma, KS; Wei, JC | 1 |
| Nuki, G; Riches, P | 1 |
| Eliseev, MS; Novikova, AM | 1 |
| Jatuworapruk, K; Lertnawapan, R | 1 |
| Hsu, CN; Huang, YB; Lee, CT; Peng, YL; Tain, YL; Wen, YH; Yang, YH | 1 |
| Andrés, M; Blanco Cáceres, BA; Calvo-Aranda, E; Diaz-Torne, C; Pascual, E; Pérez Ruiz, F; Prada-Ojeda, A; Quilis, N; Sivera, F; Vela, P | 1 |
| Bang, D; Curovic, F; Igel, TF; Katz, SD; Krasnokutsky, S; Lazaro, D; Oh, C; Pike, VC; Pillinger, MH; Romero, AG; Shah, B; Toprover, M | 1 |
| Fan, M; Gu, J; Li, X; Liu, J; Schlesinger, N; Wu, X; Zhao, B | 1 |
| Barrientos-Regala, M; Castillo, RR; Macabeo, RA; Pestaño, NS; Punzalan, FER; Ramirez-Ragasa, R; Tumanan-Mendoza, B | 1 |
| Schattner, A | 1 |
| Penserga, EG; Quilisadio, JEC; Salido, EO | 1 |
| Lagumdzija, D; Muratovic, S; Omerovic, N; Pehlivanovic, B; Skrbo, S; Ziga-Smajic, N | 1 |
| Doi, Y; Fukae, S; Ikeda, S; Kawano, H; Koga, S; Maemura, K; Minami, T; Nakata, T; Tsuneto, A; Yonekura, T | 1 |
| Desai, RJ; Kim, E; Kim, SC; Lii, J; Neogi, T | 1 |
| Borghi, C; Cicero, AFG; Cincione, RI; Fogacci, F; Tocci, G | 1 |
| Clebak, KT; Croad, JR; Morrison, A | 1 |
| Deguchi, M; Furuya, A; Kato, S; Ohta, S; Suzuki, Y | 1 |
| Bardin, T; Richette, P | 1 |
| De Caterina, R; Findlay, E; Ford, I; Hallas, J; Hawkey, CJ; MacDonald, TM; Mackenzie, IS; McMurray, JJV; Nuki, G; Perez-Ruiz, F; Ralston, SH; Robertson, M; Walters, M; Webster, J | 1 |
| Onuora, S | 1 |
| Bachman, TN; Baust, JJ; Du, J; Ghosh, S; Hahn, SA; Kelley, EE; Lebensburger, JD; Lewis, SE; McMahon, B; Ofori-Acquah, SF; Oh, JY; Patel, RP; Schmidt, HM; Straub, AC; Vitturi, DA; Wang, Y; Williams, XM; Wood, KC; Yuan, S | 1 |
| Fan, B; Li, X; Zhang, P | 1 |
| Hill-McManus, D; Hughes, DA | 1 |
| Bahrudin, U; Hisatome, I; Kuwabara, M; Li, P; Maharani, N; Mahati, E; Miake, J; Ninomiya, H; Taufiq, F; Utami, SB | 1 |
| Inoue, S; Ishigaki, Y; Miyazawa, K; Nakai, D; Nakamura, Y; Nakazawa, Y; Tatsuno, T | 1 |
| Choi, HK; Solomon, DH; Yoshida, K | 1 |
| Choi, HK; Dalbeth, N; Neogi, T; Stamp, LK; Terkeltaub, R | 1 |
| Borghi, C; Desideri, G; Gerritsen, M; Giannattasio, C; Nurmohamed, MT; Rajzer, M; Tausche, AK | 1 |
| Borghi, C; Cicero, AFG; Fogacci, F; Kuwabara, M | 1 |
| Ito, K; Kashiwagi, Y; Kimura, H; Nagoshi, T; Oi, Y; Takahashi, H; Tanaka, TD; Tanaka, Y; Yoshii, A; Yoshimura, M | 1 |
| Hirai, T; Hosohata, K; Inada, A; Iwanaga, K; Kambara, H; Nakatsuji, T; Niinomi, I; Oyama, S; Ueno, S; Wakabayashi, T | 1 |
| Estiverne, C; Mount, DB | 1 |
| Huang, X; Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Yi, HK; Zhang, JW | 1 |
| Charlton, A; MacMullan, PA | 1 |
| Desai, RJ; Kim, E; Kim, SC; Liu, J; Pawar, A | 1 |
| Ahn, SM; Hong, S; Kim, YG; Lee, CK; Oh, JS; Yoo, B | 1 |
| Becce, F; Budzik, JF; Ducoulombier, V; Lefebvre, A; Pascart, T | 1 |
| de Jong, ICA; Rongen, GA; van der Pol, KH; van Herwaarden, N | 1 |
| Cheng, R; Gao, L; Lu, Y; Pan, Y; Wang, B | 1 |
| Chen, J; Deng, Q; Guo, J; Xie, Q; Xie, S; Yu, Y; Zhang, S; Zhong, L | 1 |
| Morcos, GNB; Nadwa, EH; Salama, NM; Shafik, AN | 1 |
| Huang, H; Jiang, X; Li, G; Li, X; Liu, J; Liu, Y; Pan, Y; Sen, M; Wang, G; Yang, H; Yang, W | 1 |
| Bombardier, C; Edwards, CJ; Pardo Pardo, J; Sriranganathan, MK; Vinik, O | 1 |
| Aonuma, K; Duo, F; Ieda, M; Li, S; Mori, H; Murakata, Y; Murakoshi, N; Nogami, A; Okabe, Y; Sato, A; Shimoda, Y; Song, Z; Tajiri, K; Xu, D; Yuan, Z | 1 |
| Li, H; Sun, J; Wang, M; Wen, C; Xie, Z; Zhang, M; Zhang, Y; Zhao, T | 1 |
| Chen, H; Han, C; Li, Y; Liu, Y; Lu, T; Tu, Y; Yang, C | 1 |
| Downie, L; Riches, PL; Thomson, C | 1 |
| Farzipour, S; Ghasemi, A; Hosseinimehr, SJ; Raeispour, M; Talebpour Amiri, F | 1 |
| Ishida, S; Ishizawa, K; Kanda, M; Mitsuboshi, S; Niimura, T; Zamami, Y | 1 |
| Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Konishi, M; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 1 |
| Afinogenova, Y; Danve, A; Neogi, T | 1 |
| Ishibashi, T; Kobayashi, A; Konno, I; Kunii, H; Machii, H; Miyamoto, T; Nakazato, K; Niizeki, T; Nozaki, N; Suzuki, S; Takeishi, Y; Tsuda, A; Tsuda, T; Yamaguchi, O; Yamaki, T; Yokokawa, T; Yoshihisa, A | 1 |
| Billington, K; Bursill, D; Dalbeth, N; Doyle, AJ; Gamble, GD; Horne, A; Latto, K; Mihov, B; Murdoch, R; Narang, R; Parshu Ram, T; Stamp, LK; Tan, P | 1 |
| Chen, S; Deng, W; Huang, Q; Huang, Y; Huang, Z; Lee, PY; Li, T; Zheng, S | 1 |
| Blake, KEG; Saag, JL; Saag, KG | 1 |
| Eguchi, K; Fukumoto, Y; Ishizu, T; Kario, K; Kato, T; Node, K; Ohishi, M; Shiina, K; Takase, B; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Yoshida, H | 1 |
| Fairbanks, L; Gibson, T; Löffler, W | 1 |
| Jiang, SL; Lou, YY; Lu, XY; Shi, JH; Zhou, KL | 1 |
| Gruber, F; Kossmeier, M; Leitner, S; Litschauer, B; Reichardt, B; Sibinovic, S; Weisshaar, S; Wolzt, M | 1 |
| Gu, M; Kong, W; Yu, X; Zhang, L; Zhu, Y; Zou, Y | 1 |
| Deng, JH; Zhang, JX | 1 |
| Cheng, R; Gao, L; Wang, B | 1 |
| Kawada, T | 2 |
| Choi, J; Ghang, BZ; Kim, J; Lee, JS; Yoo, B | 1 |
| Burianov, OA; Danyliuk, SV; Khimion, LV; Nayshtetik, IM; Rotova, SO; Smiyan, SI; Trofanchuk, VV | 1 |
| Chen, Y; Cheng, X; Cui, L; Dalbeth, N; He, Y; Hu, S; Ji, A; Li, C; Li, H; Liu, Z; Lu, J; Ma, L; Qi, H; Ran, Z; Sun, M; Terkeltaub, R; Wang, C; Xue, X; Yan, F; Yu, Q; Yuan, X | 1 |
| Cai, C; Chen, M; Cui, C; Lin, Z; Liu, H; Qin, H; Zheng, B; Zhu, Y | 1 |
| Du, YW; Li, XN; Liu, HB; Wang, TT; Wang, W | 1 |
| Bittleman, D; Coras, R; Dadpey, B; Guma, M; Hamilton, B; Lauro, K; Liu-Bryan, R; Mikuls, TR; Quehenberger, O; Reilly, SM; Terkeltaub, R; Thorisdottir, H | 1 |
| Deng, JH; Zhang, JX; Zhong, GW | 1 |
| Choi, SR; Ha, YJ; Han, M; Kang, EH; Lee, EB; Lee, YJ; Shin, A | 1 |
| Steurer, J | 1 |
| Kang, SM; Kim, LH; Kwon, KW; Shin, SJ; Whang, J | 1 |
| Kobayashi, Y; Koide, Y; Matsunaga, K; Node, K; Saito, Y; Tanaka, A; Uchida, D; Ueyama, C; Yokota, N; Yoshida, H | 1 |
| Cao, Y; Deng, Y; Jiang, X; Li, C; Li, X; Lin, P; Ma, Y; Sun, F; Tao, Y; Wang, C; Yu, Q; Zhu, Y | 1 |
| Hou, C; Li, Y; Ren, J; Sha, W; Yao, M | 1 |
| Cheng, H; Hou, X; Li, X; Nan, G; Ren, L; Tian, J; Xiao, Z; Yan, D; Yang, Y; Ye, F | 1 |
| Meng, J; Xu, C | 1 |
| Iguchi, T; Ishiguro, C; Kajiyama, K; Kimura, R; Nakazato, Y; Oniyama, Y; Sawada, S; Shida, H; Uyama, Y | 1 |
| Ghang, B; Jeong, W; Kim, J; Lee, J | 1 |
| Choi, E; Jeong, H; Kim, B; Suh, A; Yoo, M | 1 |
| Cao, B; Yang, N | 1 |
| Chen, M; Cui, R; Dai, SM; Du, Y; Tong, Q; Wang, SI; Wei, JC | 1 |
| Cui, J; Hou, J; Wang, W; Zhang, X | 1 |
| Kotake, K; Mitsuboshi, S | 1 |
| Kuo, CF; Li, PR; Liu, JR; See, LC; Tsai, PH | 1 |
| Bryner, RW; Burrage, EN; Chantler, PD; Childers, R; Coblentz, T; DeVallance, E; Kelley, EE; Lewis, SE; Prabhu, SS | 1 |
| Domingues, V; Gorlitsky, B; Guedes, M; Karaboyas, A; LaMoreaux, B; Lew, S; Marder, B; Pecoits-Filho, R; Rivara, MB; Robinson, B; Zhao, J | 1 |
| Chen, X; Feng Li, H; Hong, Y; Li, Z; Wang, G; Wang, Y; Wu, W; Zhang, X; Zhou, C; Zhou, D | 1 |
| Chang, YK; Choi, WJ; Hong, YA; Kim, SY; Park, CW; Yang, KJ | 1 |
| Mironova, OI | 1 |
| Do, JY; Kang, SH; Kim, BY; Kim, GO; Son, EJ | 1 |
| Fujii, M; Fukuoka, T; Hirohata, S; Honma, K; Kakimoto, M; Kirihara, S; Kitamori, K; Nakayama, H; Ran, S; Sato, I; Watanabe, S; Yamamoto, S | 1 |
| Kim, AR; Lee, SG; So, MW | 1 |
| Bai, Y; Fang, Z; Li, Y; Tang, L; Wang, Q; Wang, X; Xu, T; Zhang, C; Zhang, T; Zhang, Y | 1 |
| Bowers, MS; Cole, BK; Feaver, RE; Figler, RA; Henke, BR; Hoang, S; Johns, BA; LaMoreaux, BD; Lawson, MJ; Nyborg, AC; Taylor, J; Wamhoff, BR; Zhao, L | 1 |
108 review(s) available for febuxostat and allopurinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.
Topics: Allopurinol; Computer Simulation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Humans; Molecular Structure; Structure-Activity Relationship; Xanthine Oxidase | 2017 |
Pharmacological urate-lowering approaches in chronic kidney disease.
Topics: Biological Products; Drug Discovery; Flavonoids; Humans; Renal Insufficiency, Chronic; Uric Acid | 2019 |
[Development antihyperuricemic candidates].
Topics: Animals; Drug Design; Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Pyrazoles; Tetrazoles; Thiazoles; Urate Oxidase; Uricosuric Agents; Xanthine Oxidase | 2003 |
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Losartan; Pyrazoles; Thiazoles; Treatment Outcome; Urate Oxidase; Uric Acid; Xanthine Oxidase | 2004 |
Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Topics: Disease Management; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2005 |
An update on the treatment options for gout and calcium pyrophosphate deposition.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Allopurinol; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Chondrocalcinosis; Colchicine; Drug Combinations; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Multicenter Studies as Topic; Probenecid; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2005 |
Newer therapeutic approaches: gout.
Topics: Anti-Inflammatory Agents; Arthritis, Gouty; Febuxostat; Humans; Thiazoles; Urate Oxidase; Uricosuric Agents; Xanthine Oxidase | 2006 |
New developments in clinically relevant mechanisms and treatment of hyperuricemia.
Topics: Febuxostat; Humans; Hyperuricemia; Prognosis; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2006 |
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
Topics: Febuxostat; Gout; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2006 |
Uricase and other novel agents for the management of patients with treatment-failure gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiazoles; Treatment Failure; Urate Oxidase; Uric Acid | 2007 |
[Inhibitors of xanthine oxidoreductase].
Topics: Allopurinol; Drug Design; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Nitriles; Pyrazoles; Pyridines; Thiazoles; Xanthine Dehydrogenase | 2008 |
Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
Topics: Animals; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Patents as Topic; Thiazoles; Xanthine Oxidase | 2007 |
Update on emerging urate-lowering therapies.
Topics: Allopurinol; Drug Discovery; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Thiazoles; United States; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2009 |
Febuxostat: a new treatment for hyperuricaemia in gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Topics: Allopurinol; Cost-Benefit Analysis; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
Approach to the treatment of hyperuricemia.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2009 |
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Topics: Allopurinol; Biotransformation; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Half-Life; Humans; Hyperuricemia; Thiazoles; Tissue Distribution; Uric Acid; Xanthine Dehydrogenase; Xanthine Oxidase | 2009 |
Progress in the pharmacotherapy of gout.
Topics: Allopurinol; Clinical Trials as Topic; Colchicine; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Recombinant Fusion Proteins; Thiazoles; Uricosuric Agents | 2010 |
Management of hyperuricemia in gout: focus on febuxostat.
Topics: Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2010 |
International position paper on febuxostat.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; International Cooperation; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2010 |
Urate-lowering therapy for gout: focus on febuxostat.
Topics: Clinical Trials as Topic; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Thiazoles; Xanthine Oxidase | 2010 |
[The clinical picture of gout is changing].
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Probenecid; Risk Factors; Thiazoles; Uricosuric Agents | 2010 |
Gout therapeutics: new drugs for an old disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; Enzyme Inhibitors; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Thiazoles; United States; United States Food and Drug Administration; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2011 |
Advances in gout: some answers, more questions.
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles | 2010 |
Febuxostat, a nonpurine selective inhibitor of xanthine oxidase: a promising medical therapy for chronic heart failure?
Topics: Animals; Chronic Disease; Febuxostat; Heart Failure; Humans; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase | 2010 |
Crystal arthropathies: recognizing and treating "the gouch".
Topics: Allopurinol; Antimetabolites; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric Acid; Uricosuric Agents | 2010 |
Managing gout: how is it different in patients with chronic kidney disease?
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Comorbidity; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Kidney Failure, Chronic; Risk Factors; Thiazoles | 2010 |
Febuxostat for treatment of chronic gout.
Topics: Allopurinol; Animals; Chronic Disease; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2011 |
[Treatment of gout].
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Uric Acid; Uricosuric Agents | 2011 |
Managing your patient with gout: a review of treatment options.
Topics: Allopurinol; Anti-Inflammatory Agents; Colchicine; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Life Style; Patient Education as Topic; Quality of Life; Risk Factors; Thiazoles | 2011 |
[Febuxostat].
Topics: Allopurinol; Enzyme Activation; Febuxostat; Gout; Gout Suppressants; Humans; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid; Xanthine Oxidase | 2011 |
A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Primary Health Care; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
[New therapeutic options for gout].
Topics: Allopurinol; Controlled Clinical Trials as Topic; Drug Approval; Drugs, Investigational; Febuxostat; Gout; Gout Suppressants; Humans; Interleukin-1beta; Organic Anion Transporters; Polyethylene Glycols; Recombinant Proteins; Thiazoles; Urate Oxidase | 2011 |
[Gout - regardless of therapeutic options a "forgotten" disease].
Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Cytokines; Europe; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Inflammasomes; Interleukin-1; Long-Term Care; Probenecid; Signal Transduction; Thiazoles; Uric Acid | 2011 |
[Hyperuricemia, gout, pseudogout and concomitant diseases].
Topics: Allopurinol; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chondrocalcinosis; Comorbidity; Diabetes Mellitus, Type 2; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Hypertrophy, Left Ventricular; Hyperuricemia; Interleukin 1 Receptor Antagonist Protein; Kidney Failure, Chronic; Thiazoles; Xanthine Oxidase | 2011 |
Recent advances in management of gout.
Topics: Adrenal Cortex Hormones; Alcohol Drinking; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Ascorbic Acid; Colchicine; Comorbidity; Cryotherapy; Diet; Dose-Response Relationship, Drug; Febuxostat; Fructose; Gout; Gout Suppressants; Humans; Interleukin 1 Receptor Antagonist Protein; Polyethylene Glycols; Purines; Receptors, Interleukin-1; Recombinant Fusion Proteins; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Vitamins; Xanthine Oxidase | 2012 |
Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Comorbidity; Contraindications; Febuxostat; Glucocorticoids; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Probenecid; PubMed; Renal Insufficiency, Chronic; Secondary Prevention; Thiazoles; Urate Oxidase | 2012 |
[Gout: an overview of available urate lowering therapies].
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Guidelines as Topic; Humans; Organ Transplantation; Polyethylene Glycols; Thiazoles; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2012 |
[Gout and other crystal-induced arthritides].
Topics: Absorptiometry, Photon; Aged; Allopurinol; Arthritis, Gouty; Chondrocalcinosis; Cross-Sectional Studies; Enzymes, Immobilized; Evidence-Based Medicine; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Risk Factors; Thiazoles; Ultrasonography; Urate Oxidase | 2012 |
Safety of urate-lowering therapies: managing the risks to gain the benefits.
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Risk Factors; Thiazoles; Uric Acid | 2012 |
Febuxostat for treating chronic gout.
Topics: Allopurinol; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Randomized Controlled Trials as Topic; Thiazoles | 2012 |
Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Febuxostat; Heart Failure; Humans; Inflammation; Ischemia; Rabbits; Rats; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2013 |
Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid | 2013 |
A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2013 |
Tumor lysis syndrome: new challenges and recent advances.
Topics: Acute Kidney Injury; Allopurinol; Bicarbonates; Buffers; Calcium; Diuretics; Enzyme Inhibitors; Febuxostat; Fluid Therapy; Humans; Hyperkalemia; Hyperphosphatemia; Hyperuricemia; Hypocalcemia; Renal Dialysis; Thiazoles; Tumor Lysis Syndrome; Urate Oxidase | 2014 |
Safety profile of anti-gout agents: an update.
Topics: Allopurinol; Colchicine; Drug Interactions; Febuxostat; Gout; Gout Suppressants; HLA-B Antigens; Humans; Interleukin-1; Polyethylene Glycols; Risk Factors; Safety; Thiazoles; Urate Oxidase | 2014 |
Febuxostat: drug review and update.
Topics: Animals; Arthritis, Gouty; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Hepatic Insufficiency; Humans; Hyperuricemia; Liver; Thiazoles; Xanthine Oxidase | 2014 |
Treatment of calcium nephrolithiasis in the patient with hyperuricosuria.
Topics: Allopurinol; Biomarkers; Calcium Oxalate; Febuxostat; Humans; Indapamide; Kidney; Nephrolithiasis; Risk Factors; Treatment Outcome; Uric Acid; Uricosuric Agents | 2014 |
Therapeutic approaches to chronic hyperuricemia and gout.
Topics: Allopurinol; Cardiovascular Diseases; Chronic Disease; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Life Style; Patient Education as Topic; Thiazoles; Xanthine Oxidase | 2014 |
Long-term management of gout: nonpharmacologic and pharmacologic therapies.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Febuxostat; Feeding Behavior; Gout; Gout Suppressants; Humans; Hyperuricemia; Polyethylene Glycols; Risk Reduction Behavior; Thiazoles; Urate Oxidase; Uricosuric Agents | 2014 |
Clinical inquiry: Which prophylactic therapies best prevent gout attacks?
Topics: Allopurinol; Colchicine; Evidence-Based Medicine; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Quality of Life; Thiazoles; Urate Oxidase | 2014 |
Allopurinol for chronic gout.
Topics: Allopurinol; Benzbromarone; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Probenecid; Randomized Controlled Trials as Topic; Thiazoles; Uric Acid | 2014 |
Advances in pharmacotherapy for the treatment of gout.
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzbromarone; Clinical Trials, Phase III as Topic; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Probenecid; Thiazoles; Urate Oxidase; Uric Acid | 2015 |
Febuxostat for the treatment of gout.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Xanthine Oxidase | 2015 |
[A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Uric Acid | 2014 |
[Hyperuricemia. When and how to treat?].
Topics: Allopurinol; Evidence-Based Medicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Internationality; Practice Guidelines as Topic; Treatment Outcome; Uricosuric Agents | 2016 |
Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2016 |
Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Topics: Allopurinol; Animals; Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Reactive Oxygen Species; Risk Factors; Xanthine Dehydrogenase | 2016 |
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.
Topics: Allopurinol; Asymptomatic Diseases; Drug Eruptions; Drug Hypersensitivity; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Uricosuric Agents; Urolithiasis | 2017 |
Pathogenesis and Clinical Management of Gouty Arthritis.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Gouty; Colchicine; Diet, Healthy; Febuxostat; Fluid Therapy; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Interleukin 1 Receptor Antagonist Protein; Polyethylene Glycols; Smoking Cessation; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2015 |
Xanthine oxidoreductase and its inhibitors: relevance for gout.
Topics: Allopurinol; Animals; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hypoxanthine; Uric Acid; Xanthine Dehydrogenase | 2016 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Patient Care Planning; Probenecid; Renal Insufficiency, Chronic; Uric Acid; Uricosuric Agents | 2017 |
Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
Topics: Adult; Allopurinol; Arthritis, Gouty; Cardiovascular Diseases; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome; Urate Oxidase | 2017 |
Lesinurad: A Review in Hyperuricaemia of Gout.
Topics: Adult; Allopurinol; Drug Therapy, Combination; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Kidney; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2017 |
The Role of Xanthine Oxidase Inhibitors in Patients with History of Stroke: A Systematic Review.
Topics: Allopurinol; Disability Evaluation; Endothelium, Vascular; Enzyme Inhibitors; Febuxostat; Humans; Recovery of Function; Stroke; Treatment Outcome; Xanthine Oxidase | 2018 |
Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Topics: Adult; Allopurinol; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid | 2017 |
The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function.
Topics: Allopurinol; Blood Pressure; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2017 |
Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.
Topics: Aged; Allopurinol; Enzyme Inhibitors; Febuxostat; Female; Humans; Male; Middle Aged; Nitriles; Pyridines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Xanthine Oxidase | 2017 |
[Hyperuricaemia and Chronic Kidney Disease].
Topics: Allopurinol; Arteriosclerosis; Disease Progression; Febuxostat; Humans; Hypertension; Hyperuricemia; Observational Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Factors | 2018 |
Uric Acid: The Unknown Uremic Toxin.
Topics: Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Kidney; Parenchymal Tissue; Renal Insufficiency, Chronic; Uric Acid | 2018 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Enzyme Inhibitors; Febuxostat; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Monosaccharide Transport Proteins; Nitriles; Oxidative Stress; Pyridines; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid; Xanthine Oxidase | 2018 |
Treatment of Hyperuricemia in Chronic Kidney Disease.
Topics: Allopurinol; Diet; Disease Progression; Exercise; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Life Style; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Weight Loss | 2018 |
Gout: state of the art after a decade of developments.
Topics: Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase | 2019 |
[Cardiovascular risk in gout patients : Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Risk Factors | 2018 |
International position paper on the appropriate use of uricosurics with the introduction of lesinurad.
Topics: Benzbromarone; Europe; Febuxostat; Gout; Humans; International Cooperation; Practice Guidelines as Topic; Probenecid; Rheumatology; Thioglycolates; Triazoles; Uricosuric Agents; Xanthine Oxidase | 2018 |
Gout - An update of aetiology, genetics, co-morbidities and management.
Topics: Allopurinol; Chronic Disease; Comorbidity; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thioglycolates; Triazoles; Uric Acid | 2018 |
The Challenges of Approaching and Managing Gout.
Topics: Acetamides; Allopurinol; Antibodies, Monoclonal, Humanized; Colchicine; Diet Therapy; Febuxostat; Gout; Gout Suppressants; Humans; Medication Adherence; Patient Education as Topic; Phenylacetates; Polyethylene Glycols; Quality of Health Care; Rheumatology; Thioglycolates; Triazoles; Urate Oxidase; Uric Acid | 2019 |
Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population-Based Cohort Study and Meta-Analysis.
Topics: Aged; Allopurinol; Asian People; Cardiovascular Diseases; Cohort Studies; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Febuxostat; Gout; Gout Suppressants; Humans; Middle Aged; Taiwan | 2019 |
Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Topics: Allopurinol; Anti-Inflammatory Agents; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid | 2019 |
Febuxostat administration for the prevention of tumour lysis syndrome: A meta-analysis.
Topics: Allopurinol; Animals; Febuxostat; Gout Suppressants; Humans; Tumor Lysis Syndrome; Uric Acid | 2019 |
Cardiovascular Safety of Urate Lowering Therapies.
Topics: Allopurinol; Cardiovascular Diseases; Endothelium; Febuxostat; Gout; Gout Suppressants; Heart Failure; Humans; Hypertension; Hyperuricemia; Myocardial Infarction; Probenecid; Risk; Stroke; Uricosuric Agents; Xanthine Oxidase | 2019 |
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Topics: Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2019 |
Debates in gout management.
Topics: Allopurinol; Disease Management; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Quality of Life | 2020 |
Successful Desensitization to Febuxostat in a Patient With Hypersensitivity to Allopurinol and Febuxostat and Review of the Literature.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome | 2021 |
Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies.
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Heart Failure; Humans; Oxypurinol; Uric Acid; Xanthine Oxidase | 2020 |
Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Humans; Hyperuricemia; Risk Assessment; Uric Acid | 2020 |
Efficacy and safety of urate-lowering treatments in patients with hyperuricemia: A comprehensive network meta-analysis of randomized controlled trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Uric Acid | 2020 |
Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Uric Acid | 2020 |
Changing paradigms in the management of gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid | 2020 |
Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2021 |
The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Topics: Aged; Allopurinol; Biomarkers; Blood Pressure; Febuxostat; Female; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Uric Acid | 2020 |
Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients.
Topics: Allopurinol; Benzaldehydes; Chronic Disease; Comorbidity; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Nitriles; Pyridines; Randomized Controlled Trials as Topic; Xanthine Oxidase | 2021 |
Gout: Rapid Evidence Review.
Topics: Adrenal Cortex Hormones; Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Obesity; Risk Factors; Sex Factors; Uric Acid | 2020 |
Efficacy and safety of Febuxostat Versus Allopurinol in Hyperuricemic patients with or without Gout: A meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome | 2020 |
Medications for gout and its comorbidities: mutual benefits?
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Observational Studies as Topic; Symptom Flare Up | 2021 |
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
Topics: Acetamides; Allopurinol; Benzbromarone; Chronic Disease; Evidence-Based Medicine; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Naphthalenes; Nitriles; Phenylacetates; Polyethylene Glycols; Probenecid; Propionates; Pyridines; Thioglycolates; Triazoles; Urate Oxidase; Uricosuric Agents; Xanthine Oxidase | 2021 |
The Management of Gout in Renal Disease.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia | 2020 |
Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Myocardial Infarction | 2021 |
The association between urate-lowering therapies and treatment-related adverse events, liver damage, and major adverse cardiovascular events (MACE): A network meta-analysis of randomized trials.
Topics: Allopurinol; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Uric Acid | 2021 |
Interventions for tophi in gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Polyethylene Glycols; Randomized Controlled Trials as Topic; Thioglycolates; Triazoles; Urate Oxidase | 2021 |
The major cardiovascular events of febuxostat versus allopurinol in treating gout or asymptomatic hyperuricemia: a systematic review and meta-analysis.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2021 |
Update on gout management: what is old and what is new.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Symptom Flare Up | 2022 |
What's new on the front-line of gout pharmacotherapy?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Quality of Life; Uric Acid | 2022 |
Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
Topics: Allopurinol; Bayes Theorem; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Research Progress of Natural Active Substances with Uric-Acid-Reducing Activity.
Topics: Allopurinol; Febuxostat; Humans; Hyperuricemia; Kidney; Uric Acid; Xanthine Oxidase | 2022 |
Association between use of febuxostat and muscle injury: A disproportionality analysis and meta-analysis of randomized controlled trials.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Muscles; Muscular Diseases; Randomized Controlled Trials as Topic; Rhabdomyolysis | 2023 |
[Hyperuricemia and kidney damage in patients with cardiovascular disease: A review].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Renal Insufficiency, Chronic; Uric Acid | 2023 |
71 trial(s) available for febuxostat and allopurinol
| Article | Year |
|---|---|
Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Topics: Adult; Area Under Curve; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Humans; Liver; Male; Placebos; Purines; Thiazoles; Time Factors; Uric Acid; Xanthine Oxidase | 2004 |
PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
Topics: Area Under Curve; Enzyme Inhibitors; Febuxostat; Female; Humans; Kidney; Kidney Diseases; Male; Renal Insufficiency; Thiazoles; Time Factors; Xanthine Oxidase | 2004 |
Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
Topics: Area Under Curve; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hyperuricemia; Male; Oxygen; Thiazoles; Time Factors; Xanthine Dehydrogenase; Xanthine Oxidase | 2004 |
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2005 |
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Topics: Allopurinol; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Uric Acid; Xanthine Oxidase | 2005 |
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Topics: Administration, Oral; Adult; Biotransformation; Drug Administration Schedule; Enzyme Inhibitors; Febuxostat; Female; Humans; Liver Diseases; Male; Middle Aged; Thiazoles; Xanthine Oxidase | 2006 |
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hypoxanthine; Male; Models, Biological; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase | 2006 |
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Linear Models; Multivariate Analysis; Odds Ratio; Thiazoles; Time Factors; Treatment Outcome | 2008 |
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Biotransformation; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hypoxanthine; Male; Protein Binding; Sex Factors; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase; Young Adult | 2008 |
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Topics: Adult; Aged; Allopurinol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2008 |
Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Chromatography, High Pressure Liquid; Febuxostat; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; Xanthine Oxidase; Young Adult | 2011 |
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Comorbidity; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Hyperuricemia; Kidney Diseases; Male; Middle Aged; Obesity; Thiazoles; Treatment Outcome; United States; Uric Acid; Young Adult | 2010 |
Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
Topics: Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Febuxostat; Female; Gout Suppressants; Humans; Hydrochlorothiazide; Male; Middle Aged; Thiazoles; Uric Acid; Xanthine Oxidase; Young Adult | 2010 |
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Administration Schedule; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2010 |
Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
Topics: Adult; Aged; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: p
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Topics: Adult; Central Nervous System Diseases; Dental Enamel; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Japan; Kidney Diseases, Cystic; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
Topics: Administration, Oral; Adult; Aged; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Oxypurinol; Renal Insufficiency; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase; Young Adult | 2011 |
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phas
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Male; Middle Aged; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2011 |
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Illinois; Male; Metabolic Diseases; Middle Aged; Obesity; Retrospective Studies; Sex Factors; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2012 |
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Liver Function Tests; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2011 |
African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Black or African American; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Thiazoles; White People; Young Adult | 2012 |
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
Topics: Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2012 |
The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline.
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Male; Middle Aged; Theophylline; Thiazoles; Xanthine Oxidase | 2012 |
Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
Topics: Allopurinol; Cardiovascular Diseases; Double-Blind Method; Febuxostat; Gout; Gout Suppressants; Humans; Prospective Studies; Thiazoles | 2012 |
Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney; Kidney Function Tests; Male; Middle Aged; Thiazoles; Treatment Outcome; Uric Acid | 2013 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial).
Topics: Aged; Albuminuria; Allopurinol; Arachidonic Acid; Blood Pressure; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creatinine; Cystatin C; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Lipoproteins, LDL; Male; Middle Aged; Pulse Wave Analysis; Stroke Volume; Thiazoles; Uric Acid | 2013 |
Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Body Mass Index; Cohort Studies; Comorbidity; Diabetes Complications; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Intention to Treat Analysis; Kidney; Lost to Follow-Up; Male; Middle Aged; Obesity; Patient Dropouts; Renal Insufficiency; Thiazoles; Xanthine Oxidase; Young Adult | 2013 |
Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
Topics: Adult; Allopurinol; Biomarkers; Calcium Oxalate; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Humans; Male; Middle Aged; Multidetector Computed Tomography; Thiazoles; Time Factors; Treatment Outcome; United States; Uric Acid; Urinary Calculi; Xanthine Oxidase | 2013 |
As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Topics: Aged; Allopurinol; Biomarkers; Chronic Disease; Enzyme Inhibitors; Febuxostat; Germany; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Inflammation Mediators; Kidney; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pulse Wave Analysis; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Vascular Stiffness; Xanthine Oxidase | 2014 |
An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Topics: Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Remission Induction; Thiazoles; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2014 |
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prospective Studies; Research Design | 2014 |
Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men.
Topics: Allopurinol; Biomarkers; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hypertension, Renal; Male; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Thiazoles; Treatment Outcome | 2014 |
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
Topics: Aged; Albuminuria; Allopurinol; C-Reactive Protein; Cardiac Surgical Procedures; Cholesterol; Creatinine; Cystatin C; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Renal Insufficiency, Chronic; Triglycerides; Uric Acid | 2015 |
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Albuminuria; beta 2-Microglobulin; Enzyme Inhibitors; Fatty Acid-Binding Proteins; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Uric Acid; Xanthine Oxidase | 2015 |
Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects.
Topics: Adult; Area Under Curve; Biomarkers; Cross-Over Studies; Down-Regulation; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Half-Life; Healthy Volunteers; Humans; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Republic of Korea; Therapeutic Equivalency; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase; Young Adult | 2015 |
A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
Topics: Administration, Oral; Adult; Allopurinol; Biomarkers; China; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Time Factors; Treatment Outcome; Uric Acid | 2015 |
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Febuxostat; Female; Follow-Up Studies; Gout Suppressants; Hematologic Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Risk Factors; Tumor Lysis Syndrome; Uric Acid; Young Adult | 2015 |
Effect of Febuxostat, a Xanthine Oxidase Inhibitor, on Cardiovascular Risk in Hyperuricemic Patients with Hypertension: A Prospective, Open-label, Pilot Study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Renin-Angiotensin System; Risk Factors; Treatment Outcome; Xanthine Oxidase | 2015 |
Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
Topics: Administration, Oral; Adult; Alleles; Allopurinol; China; Febuxostat; Female; Gout; Gout Suppressants; HLA-B Antigens; Humans; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Uric Acid | 2016 |
Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Neoplasms; Thiazoles; Tumor Lysis Syndrome; Uric Acid; Xanthine Oxidase; Young Adult | 2016 |
Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery, Common; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Risk Factors; Uric Acid; Xanthine Oxidase; Young Adult | 2016 |
New urate depositions on dual-energy computed tomography in gouty arthritis during urate-lowering therapy.
Topics: Acute Disease; Adult; Allopurinol; Arthritis, Gouty; Biomarkers; C-Reactive Protein; Febuxostat; Female; Foot Joints; Gout Suppressants; Humans; Male; Middle Aged; Statistics, Nonparametric; Tomography, X-Ray Computed; Uric Acid | 2017 |
Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study.
Topics: Administration, Oral; Adult; Alanine Transaminase; Arginine; Aspartate Aminotransferases; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Febuxostat; Female; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Pancytopenia; Placebos; Prospective Studies; Renal Dialysis; Risk Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2017 |
Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Topics: Adult; Aged; Antihypertensive Agents; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Enzyme Inhibitors; Febuxostat; Female; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; North America; Proof of Concept Study; Prospective Studies; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2017 |
The influence of febuxostat on coronary artery endothelial dysfunction in patients with coronary artery disease: A phase 4 randomized, placebo-controlled, double-blind, crossover trial.
Topics: Coronary Artery Disease; Coronary Vessels; Cross-Over Studies; Double-Blind Method; Drug Monitoring; Endothelium, Vascular; Febuxostat; Female; Gout Suppressants; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oxidative Stress; Treatment Outcome; Xanthine Oxidase | 2018 |
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Cause of Death; Double-Blind Method; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged | 2018 |
Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial.
Topics: Adult; Allopurinol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Dosage Calculations; Drug Monitoring; Febuxostat; Gout; Gout Suppressants; Humans; Male; Medication Therapy Management; Middle Aged; Practice Guidelines as Topic; Treatment Outcome; United States; United States Department of Veterans Affairs; Uric Acid; Veterans Health | 2018 |
The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Double-Blind Method; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Treatment Outcome; Uric Acid | 2018 |
Efficacy of high dose Allopurinol in reducing left ventricular mass in patients with left ventricular hypertrophy by comparing its efficacy with Febuxostat - a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Allopurinol; Antimetabolites; Blood Pressure; Dose-Response Relationship, Drug; Echocardiography; Febuxostat; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Treatment Outcome; Ventricular Function, Left; Young Adult | 2018 |
Does the provision of a DVD-based audio-visual presentation improve recruitment in a clinical trial? A randomised trial of DVD trial invitations.
Topics: Aged; Allopurinol; Audiovisual Aids; Febuxostat; Female; Gout; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Education as Topic; Patient Selection | 2019 |
Role of Molybdenum-Containing Enzymes in the Biotransformation of the Novel Ghrelin Receptor Inverse Agonist PF-5190457: A Reverse Translational Bed-to-Bench Approach.
Topics: Administration, Oral; Alcoholism; Aldehyde Oxidase; Animals; Azetidines; Biotransformation; Cytosol; Febuxostat; Female; Ghrelin; Hepatocytes; Humans; Liver; Mice; Microsomes, Liver; Molybdenum; Raloxifene Hydrochloride; Receptors, Ghrelin; Spiro Compounds; Xanthine Oxidase | 2019 |
Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Topics: Aged; Antioxidants; Biomarkers; Cross-Over Studies; Down-Regulation; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Nitriles; Pyridines; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2020 |
Severe Hypouricemia Impairs Endothelium-Dependent Vasodilatation and Reduces Blood Pressure in Healthy Young Men: A Randomized, Placebo-Controlled, and Crossover Study.
Topics: Adult; Blood Pressure; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Febuxostat; Humans; Male; Microvessels; Severity of Illness Index; Urate Oxidase; Uric Acid; Vasodilation; Xanthine Oxidase; Young Adult | 2019 |
Class effect of xanthine oxidase inhibitors on flow-mediated dilatation in hypertensive patients: A randomized controlled trial.
Topics: Aged; Allopurinol; Dilatation; Febuxostat; Gout; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Treatment Outcome; Xanthine Oxidase | 2020 |
Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Topics: Administration, Oral; Adult; Allopurinol; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cross-Over Studies; Drug Interactions; Febuxostat; Female; Healthy Volunteers; Humans; Intestinal Mucosa; Intestine, Small; Male; Neoplasm Proteins; Rosuvastatin Calcium; Young Adult | 2020 |
Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Topics: Adiponectin; Aged; Arginine; Benzbromarone; Cross-Over Studies; Endothelium, Vascular; Febuxostat; Female; Gout Suppressants; Humans; Hyperemia; Hyperuricemia; Male; Middle Aged; Organic Anion Transporters; Organic Cation Transport Proteins; Treatment Outcome; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2020 |
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Denmark; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Male; Prospective Studies; Sweden; Treatment Outcome; United Kingdom; Uric Acid | 2020 |
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study.
Topics: Adult; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Pulse Wave Analysis; Risk Factors; Thiazoles; Treatment Outcome; Uric Acid | 2022 |
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome | 2022 |
Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.
Topics: Allopurinol; Febuxostat; Heart Failure; Humans; Hyperuricemia; Uric Acid | 2021 |
Intensive Serum Urate Lowering With Oral Urate-Lowering Therapy for Erosive Gout: A Randomized Double-Blind Controlled Trial.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Quality of Life; Treatment Outcome; Uric Acid | 2022 |
Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE study.
Topics: Ankle Brachial Index; Atherosclerosis; Awards and Prizes; Carotid Artery Diseases; Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Prospective Studies; Pulse Wave Analysis; Uric Acid; Vascular Stiffness; Xanthine Oxidase | 2022 |
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2022 |
Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Prospective Studies; Treatment Outcome; Uric Acid | 2022 |
Impact of febuxostat on visit-to-visit blood pressure variability: insights from the randomised PRIZE Study.
Topics: Awards and Prizes; Blood Pressure; Carotid Intima-Media Thickness; Febuxostat; Humans; Hyperuricemia; Uric Acid; Xanthine Oxidase | 2022 |
A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia.
Topics: Drug Interactions; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2023 |
Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk.
Topics: Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Heart Disease Risk Factors; Humans; Risk Factors; United States; Xanthine Oxidase | 2023 |
308 other study(ies) available for febuxostat and allopurinol
| Article | Year |
|---|---|
Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.
Topics: Animals; Computer Simulation; Cytosine; Enzyme Activation; Enzyme Inhibitors; Hyperuricemia; Male; Oxonic Acid; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Xanthine Oxidase | 2012 |
Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia.
Topics: Administration, Oral; Animals; Cytosine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Hyperuricemia; Models, Molecular; Molecular Structure; Rats; Rats, Sprague-Dawley; Rats, Wistar; Structure-Activity Relationship; Time Factors; Xanthine Oxidase | 2012 |
Lead optimization of isocytosine-derived xanthine oxidase inhibitors.
Topics: Administration, Oral; Animals; Catalytic Domain; Cytosine; Enzyme Activation; Enzyme Inhibitors; Inhibitory Concentration 50; Models, Animal; Models, Molecular; Molecular Structure; Rats; Xanthine Oxidase | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Microwave assisted synthesis of naphthopyrans catalysed by silica supported fluoroboric acid as a new class of non purine xanthine oxidase inhibitors.
Topics: Borates; Catalysis; Enzyme Inhibitors; Microwaves; Naphthalenes; Pyrans; Silicon Dioxide; Xanthine Oxidase | 2014 |
HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.
Topics: Animals; Binding Sites; Drug Evaluation, Preclinical; Enzyme Activation; Enzyme Inhibitors; Gout Suppressants; Half-Life; High-Throughput Screening Assays; Hyperuricemia; Magnetic Resonance Spectroscopy; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidinones; Rats; Structure-Activity Relationship; Xanthine Oxidase | 2014 |
X-ray crystal structure of a xanthine oxidase complex with the flavonoid inhibitor quercetin.
Topics: Animals; Antioxidants; Catalytic Domain; Cattle; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Humans; Molecular Conformation; Molecular Structure; Molybdenum; Phenylalanine; Quercetin; Structure-Activity Relationship; Uric Acid; Xanthine; Xanthine Oxidase | 2014 |
Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors.
Topics: Administration, Oral; Animals; Binding Sites; Cattle; Drug Design; Enzyme Inhibitors; Half-Life; Hyperuricemia; Microsomes, Liver; Molecular Docking Simulation; Protein Structure, Tertiary; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiazoles; Uric Acid; Xanthine Oxidase | 2016 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors.
Topics: Animals; Carboxylic Acids; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hyperuricemia; Mice; Mice, Inbred ICR; Models, Molecular; Molecular Structure; Oxonic Acid; Pyrazoles; Structure-Activity Relationship; Xanthine Dehydrogenase | 2017 |
Design, synthesis and bioevaluation of 3-oxo-6-aryl-2,3-dihydropyridazine-4-carbohydrazide derivatives as novel xanthine oxidase inhibitors.
Topics: Animals; Binding Sites; Catalytic Domain; Cattle; Drug Design; Enzyme Inhibitors; Hydrazines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship; Xanthine Oxidase | 2019 |
Benzoflavone derivatives as potent antihyperuricemic agents.
Topics: | 2019 |
Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors.
Topics: Animals; Carboxylic Acids; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Female; Male; Mice; Mice, Inbred Strains; Molecular Structure; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Xanthine Oxidase | 2019 |
Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives.
Topics: Animals; Carboxylic Acids; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Female; Hyperuricemia; Male; Mice; Mice, Inbred Strains; Molecular Structure; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Xanthine Oxidase | 2019 |
Synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenylpyrimidine derivatives with 4-amino or 4-hydroxy as a pharmacophore element binding with xanthine oxidase active site.
Topics: Animals; Catalytic Domain; Dose-Response Relationship, Drug; Enzyme Inhibitors; Male; Models, Molecular; Molecular Structure; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Uric Acid; Xanthine Oxidase | 2021 |
Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.
Topics: Animals; Cattle; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Hyperuricemia; Male; Milk; Models, Molecular; Molecular Structure; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Xanthine Oxidase | 2022 |
Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxid
Topics: Allopurinol; Carboxylic Acids; Drug Design; Enzyme Inhibitors; Febuxostat; Humans; Hydrogen Bonding; Models, Molecular; Pyrimidines; Structure-Activity Relationship; Uric Acid; Xanthine Oxidase | 2022 |
Determination of plasma purine nucleoside phosphorylase activity by high-performance liquid chromatography.
Topics: Adult; Aged; Asthma; Calibration; Chromatography, High Pressure Liquid; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypoxanthine; Hypoxanthines; Inosine; Male; Middle Aged; Purine-Nucleoside Phosphorylase; Thiazoles; Uric Acid; Xanthine Oxidase | 1995 |
Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees.
Topics: Administration, Oral; Allopurinol; Animals; Dose-Response Relationship, Drug; Febuxostat; Female; Gout; Macaca mulatta; Male; Pan troglodytes; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase; Xanthines | 1993 |
Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.
Topics: Allantoin; Allopurinol; Animals; Cattle; Febuxostat; Gout Suppressants; Male; Mice; Mice, Inbred ICR; Rats; Rats, Sprague-Dawley; Thiazoles; Uric Acid; Xanthine Dehydrogenase; Xanthine Oxidase | 1993 |
Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549.
Topics: Allopurinol; Biological Transport; Carrier Proteins; Drug Interactions; Enzyme Inhibitors; Febuxostat; Humans; Hypoxanthine; Inosine; Lung Neoplasms; Membrane Proteins; Nucleoside Transport Proteins; Nucleosides; Pentosyltransferases; Purines; Pyrimidine Phosphorylases; Thiazoles; Tumor Cells, Cultured; Uracil; Uridine; Xanthine; Xanthine Oxidase | 2000 |
Nephrotoxic effects of allopurinol in dinitrofluorobenzene-sensitized mice: comparative studies on TEI-6720.
Topics: Acute Kidney Injury; Allopurinol; Animals; Blood Urea Nitrogen; Creatinine; Dermatitis, Contact; Dinitrofluorobenzene; Enzyme Inhibitors; Febuxostat; Liver; Male; Mice; Mice, Inbred BALB C; Thiazoles; Xanthine Oxidase | 1999 |
A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
Topics: Allantoin; Allopurinol; Animals; Enzyme Inhibitors; Febuxostat; Kidney Calculi; Male; Rats; Rats, Inbred Strains; Thiazoles; Uric Acid; Xanthine; Xanthine Oxidase | 1999 |
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Topics: Animals; Enzyme Inhibitors; Febuxostat; Kinetics; Milk; Molecular Structure; Thiazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2005 |
Febuxostat (Teijin/Ipsen/TAP).
Topics: Animals; Drug Evaluation, Preclinical; Enzyme Inhibitors; Febuxostat; Gout; Humans; Patents as Topic; Randomized Controlled Trials as Topic; Structure-Activity Relationship; Thiazoles; Xanthine Oxidase | 2005 |
Febuxostat--treatment for hyperuricemia and gout?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric Acid; Xanthine Oxidase | 2005 |
Febuxostat versus allopurinol for gout.
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Treatment Refusal; Xanthine Oxidase | 2006 |
Febuxostat versus allopurinol for gout.
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Treatment Refusal; Xanthine Oxidase | 2006 |
Gout's not just for the gluttonous.
Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Risk Factors; Sex Factors; Socioeconomic Factors; Thiazoles; Uric Acid | 2006 |
[Febuxostat versus allopurinol for hyperuricemia].
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Thiazoles | 2006 |
Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure.
Topics: Animals; Blood Pressure; Cardiac Pacing, Artificial; Dogs; Febuxostat; Heart Diseases; Thiazoles; Ventricular Function, Left; Xanthine Oxidase | 2006 |
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Topics: Animals; Blood Pressure; Febuxostat; Follow-Up Studies; Gout Suppressants; Hypertension, Renal; Hyperuricemia; Kidney Glomerulus; Male; Oxonic Acid; Rats; Rats, Sprague-Dawley; Renal Circulation; Thiazoles; Uric Acid; Xanthine Oxidase | 2008 |
Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment.
Topics: Allopurinol; Animals; Body Weight; Echocardiography; Enzyme Inhibitors; Febuxostat; Heart Failure; Male; Myocardial Infarction; Myocardium; Organ Size; Rabbits; Thiazoles; Time Factors; Xanthine Oxidase | 2008 |
Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.
Topics: Animals; Blood Pressure; Body Weight; Energy Intake; Febuxostat; Fructose; Gout Suppressants; Kidney; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Renal Circulation; Thiazoles; Xanthine Oxidase | 2008 |
Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Topics: Allopurinol; Animals; Catalysis; Crystallization; Enzyme Inhibitors; Febuxostat; Molybdenum; Nitriles; Protein Conformation; Pyridines; Thiazoles; Xanthine Dehydrogenase | 2008 |
In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition.
Topics: Blood Proteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Febuxostat; Glucuronosyltransferase; Humans; Ibuprofen; In Vitro Techniques; Male; Microsomes, Liver; Protein Binding; Thiazoles; Warfarin; Xanthine Oxidase | 2008 |
Gout management: let's get it right this time.
Topics: Administration, Oral; Allopurinol; Dose-Response Relationship, Drug; Drug Evaluation; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; Uric Acid; Xanthine Oxidase | 2008 |
Febuxostat.
Topics: Chronic Disease; Drug Approval; European Union; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Thiazoles; Xanthine Oxidase | 2009 |
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hyperuricemia; Thiazoles; Treatment Outcome; Uric Acid | 2009 |
New gout treatment approved.
Topics: Administration, Oral; Drug Approval; Drug Interactions; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles; United States; United States Food and Drug Administration; Uric Acid; Xanthine Oxidase | 2009 |
Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Topics: Allopurinol; Drug Approval; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction.
Topics: Allopurinol; Animals; Constriction, Pathologic; Enzyme Inhibitors; Febuxostat; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Thiazoles; Xanthine Oxidase | 2010 |
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
Topics: Acute Disease; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Chronic Disease; Colchicine; Comorbidity; Disease Progression; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Patient Education as Topic; Quality of Life; Risk Factors; Thiazoles; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2010 |
Treatment of gout.
Topics: Aged; Allopurinol; Australia; Colchicine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Febuxostat; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Kidney Diseases; Male; Patient Compliance; Practice Guidelines as Topic; Prednisolone; Renal Dialysis; Thiazoles; Uric Acid | 2011 |
Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.
Topics: Allopurinol; Animals; Cattle; Cells, Cultured; Endothelial Cells; Enzyme Inhibitors; Febuxostat; Glycosaminoglycans; Kinetics; Oxypurinol; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase | 2011 |
Effect of acute xanthine oxidase inhibition on myocardial energetics during basal and very high cardiac workstates.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adrenergic Agonists; Allopurinol; Animals; Basal Metabolism; Biopsy; Cardiotonic Agents; Coronary Circulation; Dogs; Energy Metabolism; Enzyme Inhibitors; Febuxostat; Hemodynamics; Models, Animal; Myocardial Contraction; Myocardium; Oxygen Consumption; Phosphocreatine; Reactive Oxygen Species; Thiazoles; Time Factors; Xanthine Oxidase | 2011 |
Febuxostat efficacy in allopurinol-resistant tophaceous gout.
Topics: Allopurinol; Dose-Response Relationship, Drug; Drug Resistance; Febuxostat; Female; Gout; Gout Suppressants; Humans; Thiazoles; Treatment Failure; Treatment Outcome; Uric Acid; Young Adult | 2011 |
Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
Topics: Aged; Aged, 80 and over; Allopurinol; Drug Monitoring; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Thiazoles; Uric Acid | 2011 |
Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout.
Topics: Allopurinol; Clinical Trials as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Making; Decision Trees; Febuxostat; Gout; Gout Suppressants; Humans; Thiazoles | 2012 |
Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy.
Topics: Animals; Cell Movement; Cytokines; Disease Models, Animal; Febuxostat; Fibrosis; Kidney; Kidney Diseases; Macrophages; Male; Nephritis, Interstitial; Oxidative Stress; Rats; Rats, Sprague-Dawley; Thiazoles; Transforming Growth Factor beta; Ureteral Obstruction; Xanthine Oxidase | 2012 |
Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
Topics: Allopurinol; Chronic Disease; Contraindications; Febuxostat; Gout; Gout Suppressants; Humans; Male; Middle Aged; Probenecid; Thiazoles | 2012 |
Casebook consults: improving outcomes in gout (multimedia activity).
Topics: Adrenal Cortex Hormones; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Long-Term Care; Medication Adherence; Referral and Consultation; Thiazoles; Uric Acid | 2012 |
Adherence to uric acid treatment guidelines in a rheumatology clinic.
Topics: Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Guideline Adherence; Humans; Male; Middle Aged; Probenecid; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid | 2012 |
Pharmacokinetics of febuxostat in healthy Chinese volunteers.
Topics: Administration, Oral; Asian People; Febuxostat; Female; Food-Drug Interactions; Gout Suppressants; Humans; Indicators and Reagents; Male; Sex Characteristics; Thiazoles; Xanthine Oxidase; Young Adult | 2012 |
Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.
Topics: Animals; Apoptosis; Endoplasmic Reticulum Stress; Febuxostat; Hyperuricemia; Kidney; Kidney Tubules; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Thiazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2012 |
Febuxostat improves the local and remote organ changes induced by intestinal ischemia/reperfusion in rats.
Topics: Alanine Transaminase; Allopurinol; Animals; Aspartate Aminotransferases; Dose-Response Relationship, Drug; Febuxostat; Gout Suppressants; Intestinal Mucosa; Lipid Peroxidation; Lung; Male; Malondialdehyde; Muscle Contraction; Muscle, Smooth; Peroxidase; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Thiazoles; Tumor Necrosis Factor-alpha; Xanthine Dehydrogenase; Xanthine Oxidase | 2013 |
Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules.
Topics: Allopurinol; Animals; Desensitization, Immunologic; Drug Hypersensitivity; Febuxostat; Gout; Humans; Hyperuricemia; Product Surveillance, Postmarketing; Recombinant Proteins; Skin; Thiazoles; Urate Oxidase | 2013 |
Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats.
Topics: Animals; Blood Pressure; Desoxycorticosterone; Febuxostat; Hypertension; Male; Rats; Rats, Sprague-Dawley; Thiazoles; Xanthine Oxidase | 2013 |
Italian Society of Rheumatology recommendations for the management of gout.
Topics: Adrenal Cortex Hormones; Advisory Committees; Alcoholic Beverages; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Combined Modality Therapy; Dairy Products; Disease Management; Evidence-Based Medicine; Febuxostat; Female; Fructose; Gout; Humans; Italy; Male; Risk Factors; Smoking; Societies, Medical; Thiazoles; Uric Acid | 2013 |
A sensitive LC-MS/MS method for the quantification of febuxostat in human plasma and its pharmacokinetic application.
Topics: Chromatography, High Pressure Liquid; Febuxostat; Gout Suppressants; Humans; Limit of Detection; Liquid-Liquid Extraction; Male; Tandem Mass Spectrometry; Thiazoles; Xanthine Oxidase | 2013 |
Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout.
Topics: Allopurinol; Ambulatory Care; Colchicine; Comorbidity; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Male; Middle Aged; Office Visits; Thiazoles | 2013 |
Development of a simple LC-MS/MS method for the determination of febuxostat in human plasma and its application to a bioequivalence study.
Topics: Adult; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Febuxostat; Half-Life; Humans; Male; Mass Spectrometry; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry; Therapeutic Equivalency; Thiazoles; Xanthine Oxidase | 2013 |
Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis.
Topics: Animals; Axons; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Febuxostat; Female; Mice; Multiple Sclerosis; Myelin Sheath; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase | 2013 |
Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK.
Topics: Animals; Cell Line, Tumor; Chemokine CCL2; Dual Specificity Phosphatase 1; Febuxostat; Female; Humans; Inflammation; Lipopolysaccharides; Macrophages; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Phosphorylation; Reactive Oxygen Species; RNA, Messenger; Thiazoles; Xanthine Oxidase | 2013 |
Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Glomerular Filtration Rate; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid | 2014 |
CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
Topics: Allopurinol; Comorbidity; Disease Management; Drug Administration Schedule; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medication Adherence; Primary Health Care; Risk Factors; Severity of Illness Index; Thiazoles; United States; Uric Acid | 2014 |
Febuxostat as a novel option to optimize thiopurines' metabolism in patients with inadequate metabolite levels.
Topics: Adult; Azathioprine; Drug Interactions; Enzyme Inhibitors; Febuxostat; Female; Guanine Nucleotides; Humans; Immunosuppressive Agents; Mercaptopurine; Muscular Diseases; Thiazoles; Thionucleotides; Xanthine Oxidase | 2014 |
Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.
Topics: Adult; Aged; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Thiazoles; Uric Acid; Xanthine Oxidase | 2014 |
Febuxostat: hepatic failure.
Topics: Febuxostat; Gout Suppressants; Humans; Liver Failure; Thiazoles; Xanthine Oxidase | 2013 |
Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure.
Topics: Adrenal Cortex Hormones; Aged; Allopurinol; Arthritis, Gouty; Benzbromarone; Drug Therapy, Combination; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney Failure, Chronic; Male; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2014 |
Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients.
Topics: Aged; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Thiazoles; Xanthine Oxidase | 2014 |
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study.
Topics: Aged; Allopurinol; Black or African American; Evaluation Studies as Topic; Febuxostat; Female; Focus Groups; Gout; Gout Suppressants; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Middle Aged; Thiazoles; Uric Acid | 2014 |
Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Comparative Effectiveness Research; Drug Administration Schedule; Febuxostat; Female; Follow-Up Studies; Gout; Gout Suppressants; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid; Young Adult | 2014 |
Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Cholesterol; Cytokines; Disease Models, Animal; Endothelial Cells; Febuxostat; Gout Suppressants; Inflammation; L-Lactate Dehydrogenase; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Plaque, Atherosclerotic; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase | 2014 |
Prevalence of treatment of hyperuricemic in patients admitted to the rheumatology ward and evaluation of compliance with the 2012 ACR Guidelines.
Topics: Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Guideline Adherence; Hospitalization; Humans; Hyperuricemia; Male; Prevalence; Thiazoles; Xanthine Oxidase | 2014 |
Anakinra treatment in patients with gout and type 2 diabetes.
Topics: Aged; Aged, 80 and over; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Blood Glucose; Carbamates; Colchicine; Diabetes Mellitus, Type 2; Febuxostat; Glycated Hemoglobin; Gout; Gout Suppressants; Humans; Hyperuricemia; Hypoglycemic Agents; Insulin; Interleukin 1 Receptor Antagonist Protein; Metformin; Middle Aged; Piperidines; Treatment Outcome; Uric Acid | 2015 |
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy.
Topics: Adult; Allopurinol; Antimetabolites; Benzbromarone; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Uric Acid; Uricosuric Agents; Urolithiasis | 2014 |
Screening for selective inhibitors of xanthine oxidase from Flos Chrysanthemum using ultrafiltration LC-MS combined with enzyme channel blocking.
Topics: Apigenin; Catalytic Domain; Chromatography, Liquid; Chrysanthemum; Drugs, Chinese Herbal; Enzyme Inhibitors; Febuxostat; Flavones; Flowers; Glucosides; Gout Suppressants; Luteolin; Mass Spectrometry; Thiazoles; Ultrafiltration; Xanthine Oxidase | 2014 |
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
Topics: Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Nitriles; Pyridines; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2014 |
Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Animals; Antibiotics, Antineoplastic; Cyclooxygenase 2; Deoxyguanosine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Ectodysplasins; Febuxostat; Gout Suppressants; Kidney; Liver; Male; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Thiazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2014 |
Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Disease Progression; Drug Substitution; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Thiazoles; Treatment Outcome; Uric Acid | 2014 |
Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry.
Topics: Aged; Aged, 80 and over; Allopurinol; Cross-Sectional Studies; Febuxostat; Female; Gout Suppressants; Hospitals; Humans; Hyperuricemia; Inappropriate Prescribing; Italy; Male; Patient Admission; Patient Discharge; Registries; Risk; Thiazoles; Xanthine Oxidase | 2014 |
Cost-effectiveness of allopurinol and febuxostat for the management of gout.
Topics: Allopurinol; Cost Savings; Cost-Benefit Analysis; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Markov Chains; Models, Theoretical; Quality-Adjusted Life Years; Thiazoles | 2014 |
Adherence and persistence to urate-lowering therapies in the Irish setting.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Allopurinol; Databases, Factual; Febuxostat; Female; Gout; Gout Suppressants; Humans; Ireland; Male; Medication Adherence; Middle Aged; Retrospective Studies; Sex Factors; Uric Acid; Young Adult | 2016 |
The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Death; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Gastroesophageal Reflux; Gout Suppressants; Liver; Lung; Lung Injury; Male; Mice, Inbred C57BL; Necrosis; Neutrophil Infiltration; Peritoneum; Peritonitis; Thiazoles; Uric Acid; Xanthine Oxidase | 2015 |
Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
Topics: Aged; Allopurinol; Antineoplastic Agents; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Hematologic Neoplasms; Humans; Hypoxanthine; Male; Middle Aged; Pilot Projects; Prospective Studies; Thiazoles; Tumor Lysis Syndrome; Uric Acid; Xanthine; Xanthine Oxidase | 2014 |
Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
Topics: Allopurinol; Chronic Disease; Cost-Benefit Analysis; Febuxostat; Gout; Gout Suppressants; Humans; Markov Chains; Thiazoles; Uric Acid | 2015 |
Characteristics and management of gout patients in Europe: data from a large cohort of patients.
Topics: Adult; Allopurinol; Cohort Studies; Comorbidity; Cross-Sectional Studies; Europe; Febuxostat; Female; France; Gout; Gout Suppressants; Greece; Humans; Male; Middle Aged; Obesity; Patient Compliance; Thiazoles; Uric Acid | 2015 |
Effects of Febuxostat on Oxidative Stress.
Topics: Adult; Aged; Allopurinol; Creatinine; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Oxidative Stress; Reactive Oxygen Species; Uric Acid | 2015 |
Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antigens, Differentiation, T-Lymphocyte; Case-Control Studies; Cells, Cultured; Cross Reactions; Drug Eruptions; Enzyme-Linked Immunosorbent Assay; Febuxostat; Female; Humans; Interferon-gamma; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Middle Aged; Oxypurinol; Reference Values; Stevens-Johnson Syndrome; Thiazoles | 2015 |
Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Topics: Aged; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Managed Care Programs; Medicare; Reference Values; Retrospective Studies; Severity of Illness Index; Treatment Outcome; United States; Uric Acid | 2015 |
The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Topics: Animals; Apoptosis; Choline Deficiency; Cytoprotection; Diet, High-Fat; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Hyperuricemia; Liver; Liver Cirrhosis, Experimental; Methionine; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Thiazoles; Uric Acid; Xanthine Oxidase | 2015 |
Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Biomarkers; Body Weight; Doxorubicin; Febuxostat; Heart; Male; Organ Size; Rats; Rats, Wistar; Superoxide Dismutase; Thiazoles; Thiobarbituric Acid Reactive Substances; Xanthine Oxidase | 2015 |
Gout: Why compare the effectiveness of suboptimal gout management?
Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male | 2015 |
Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Carotid Artery Thrombosis; Case-Control Studies; Cell-Derived Microparticles; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Interleukin-6; Male; Middle Aged; Uric Acid; Xanthine Oxidase | 2015 |
Characterization and Thermodynamic Relationship of Three Polymorphs of a Xanthine Oxidase Inhibitor, Febuxostat.
Topics: Crystallization; Drug Stability; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Phase Transition; Powder Diffraction; Solubility; Thermodynamics; Transition Temperature; X-Ray Diffraction; Xanthine Oxidase | 2015 |
Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
Topics: Aged; Allopurinol; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Thyrotropin; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid; Xanthine Dehydrogenase | 2015 |
Febuxostat in the management of gout: a cost-effectiveness analysis.
Topics: Adult; Aged; Allopurinol; Cost-Benefit Analysis; Disease Management; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; United States; Uric Acid | 2016 |
A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.
Topics: Adult; Aged; Allopurinol; Comparative Effectiveness Research; Drug Monitoring; Drug Substitution; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; United States; Uric Acid; Xanthine Oxidase | 2015 |
Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.
Topics: Aged; Allopurinol; Drug Eruptions; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies | 2016 |
Febuxostat protects rats against lipopolysaccharide-induced lung inflammation in a dose-dependent manner.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; C-Reactive Protein; Dose-Response Relationship, Drug; Febuxostat; Glutathione; L-Lactate Dehydrogenase; Leukocyte Count; Lipopolysaccharides; Lung; Male; Malondialdehyde; Nitric Oxide; Pulmonary Edema; Rats, Sprague-Dawley; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Xanthine Oxidase | 2016 |
Cost-effectiveness analysis of febuxostat in patients with gout in Spain.
Topics: Allopurinol; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Markov Chains; Models, Econometric; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Renal Insufficiency; Spain | 2016 |
[Using the whole arsenal to prevent an attack].
Topics: Allopurinol; Arthritis, Gouty; Benzbromarone; Combined Modality Therapy; Febuxostat; Female; Gout; Gout Suppressants; Humans; Middle Aged; Polyethylene Glycols; Urate Oxidase | 2015 |
[Drug reduction of uric acid not just when symptoms appear].
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Gout; Humans; Hyperuricemia; Uric Acid | 2016 |
Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Cost-Benefit Analysis; Febuxostat; Female; Gout; Gout Suppressants; Health Care Costs; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Uric Acid | 2016 |
Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Topics: Aged; Allopurinol; Blood Pressure; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Humans; Hypertension; Hyperuricemia; Kidney; Male; Middle Aged; Renin-Angiotensin System; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2016 |
Effects of urate-lowering agents on arrhythmia vulnerability in post-infarcted rat hearts.
Topics: Animals; Arrhythmias, Cardiac; Febuxostat; GAP-43 Protein; Male; Myocardial Infarction; Myocardium; Nerve Growth Factor; Rats; Rats, Wistar; Superoxides; Tyrosine 3-Monooxygenase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2016 |
Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Febuxostat; Hypertension; Male; Oxidative Stress; Rats, Inbred SHR; Rats, Inbred WKY; Time Factors; Tyrosine; Vasodilation; Vasodilator Agents; Xanthine Oxidase | 2016 |
Febuxostat for Asymptomatic Hyperuricemia in CKD.
Topics: Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid; Xanthine Oxidase | 2016 |
Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.
Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cisplatin; Creatinine; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Glutathione; Inflammation Mediators; Kidney; L-Lactate Dehydrogenase; Male; Malondialdehyde; Nitric Oxide; Oxidative Stress; Proteinuria; Rats, Sprague-Dawley; Serum Albumin; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Urological Agents; Xanthine Oxidase | 2016 |
Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat.
Topics: Enzyme Inhibitors; Febuxostat; Gout Suppressants; Humans; Thiazoles; Xanthine Oxidase | 2016 |
Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Enzyme Inhibitors; Febuxostat; Male; Oxidative Stress; Rats; Rats, Zucker; Xanthine Oxidase | 2016 |
Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
Topics: Computer Simulation; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Models, Biological; Renal Insufficiency, Chronic; Uric Acid; Xanthine; Xanthine Oxidase | 2016 |
The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Topics: Adult; Aged; Allopurinol; Budgets; Chronic Disease; Febuxostat; Female; Gout; Gout Suppressants; Health Care Costs; Humans; Male; Managed Care Programs; Middle Aged; Pharmaceutical Services; Renal Insufficiency, Chronic; United States; Uric Acid; Young Adult | 2016 |
Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Thiazoles; Uric Acid | 2016 |
A novel drug management system in the Febuxostat versus Allopurinol Streamlined Trial: A description of a pharmacy system designed to supply medications directly to patients within a prospective multicenter randomised clinical trial.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Multicenter Studies as Topic; Pharmaceutical Services; Postal Service; Prospective Studies; Randomized Controlled Trials as Topic; Software | 2016 |
Tophaceous Gout in an Anorectic Patient Visualized by Dual Energy Computed Tomography (DECT).
Topics: Absorptiometry, Photon; Allopurinol; Anorexia Nervosa; Biomarkers; Biopsy; Colchicine; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Middle Aged; Patient Compliance; Predictive Value of Tests; Sensitivity and Specificity; Urate Oxidase; Uric Acid | 2016 |
Digital Tophaceous Gout.
Topics: Allopurinol; Drug Costs; Febuxostat; Fingers; Gout; Gout Suppressants; Health Equity; Humans; Male; Middle Aged; Symptom Flare Up | 2016 |
Cross-Reactions Between Allopurinol and Febuxostat.
Topics: Aged; Allopurinol; Cross Reactions; Drug Hypersensitivity Syndrome; Febuxostat; Female; Gout Suppressants; Humans | 2017 |
Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
Topics: Acute Disease; Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Uric Acid; Xanthine Oxidase | 2017 |
Febuxostat attenuates paroxysmal atrial fibrillation-induced regional endothelial dysfunction.
Topics: Animals; Atrial Fibrillation; Endothelium; Enzyme Inhibitors; Febuxostat; Heart Atria; Male; Oxidative Stress; Rabbits; Xanthine Oxidase | 2017 |
Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Drug Monitoring; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Retrospective Studies; Rheumatology; Tennessee; Uric Acid; Veterans; Xanthine Oxidase | 2017 |
A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
Topics: Adult; Allopurinol; Asian People; Benzbromarone; Biomarkers; China; Drug Dosage Calculations; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome; Uric Acid | 2017 |
The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012.
Topics: Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; British Columbia; Colchicine; Comorbidity; Diabetes Mellitus; Febuxostat; Female; Glucocorticoids; Gout; Gout Suppressants; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Middle Aged; Population Growth; Prevalence; Probenecid; Sulfinpyrazone; Uricosuric Agents | 2017 |
Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Topics: Aged; Allopurinol; Biomarkers; Drug Substitution; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Medical Audit; Medication Adherence; Practice Guidelines as Topic; Probenecid; Retrospective Studies; Rheumatology; Time Factors; Treatment Outcome; Uric Acid | 2017 |
Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
Topics: Aged; Aged, 80 and over; Drug Substitution; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Nitriles; Proteinuria; Pyridines; Renal Insufficiency, Chronic; Treatment Outcome; Xanthine Dehydrogenase; Xanthine Oxidase | 2017 |
Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice.
Topics: Animal Structures; Animals; Diabetes Mellitus; Febuxostat; Gene Expression Profiling; Gout Suppressants; Hyperuricemia; Immunohistochemistry; Intra-Abdominal Fat; Mice; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Stress, Physiological; Thrombosis; Xanthine Oxidase | 2017 |
Management of Gout and Hyperuricemia in CKD.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Diet Therapy; Disease Management; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Symptom Flare Up; Treatment Outcome; Uric Acid | 2017 |
Previous Dosage of Allopurinol Is a Strong Determinant of Febuxostat Efficacy.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Uric Acid | 2017 |
Recurrent meningoencephalitis due to allopurinol.
Topics: Aged; Allopurinol; Antimetabolites; Confusion; Febuxostat; Female; Gout Suppressants; Headache; Humans; Leukocytosis; Meningoencephalitis; Recurrence | 2018 |
Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data.
Topics: Administrative Claims, Healthcare; Aged; Aged, 80 and over; Allopurinol; Comparative Effectiveness Research; Febuxostat; Female; Gout; Gout Suppressants; Humans; Incidence; Kidney Diseases; Male; Medicare; Propensity Score; Proportional Hazards Models; Retrospective Studies; United States | 2017 |
Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis.
Topics: Allopurinol; Cost-Benefit Analysis; Drug Administration Schedule; Febuxostat; Gout; Humans; Markov Chains; Models, Economic; Research Design | 2017 |
Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
Topics: Allopurinol; Benzbromarone; Databases, Factual; Febuxostat; Gout; Gout Suppressants; Humans; Republic of Korea; Uric Acid | 2018 |
Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
Topics: Computer Simulation; Drug Therapy, Combination; Febuxostat; Gout; Gout Suppressants; Humans; Male; Medication Adherence; Models, Biological; Risk Assessment; Thioglycolates; Treatment Outcome; Triazoles; Uric Acid; Xanthine Oxidase | 2018 |
Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults.
Topics: Aged; Aged, 80 and over; Allopurinol; Dementia; Febuxostat; Female; Gout Suppressants; Humans; Male; Retrospective Studies; Risk Factors | 2018 |
Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies.
Topics: Adolescent; Age Factors; Allopurinol; Antineoplastic Agents; Biomarkers; Child; Child, Preschool; Creatinine; Down-Regulation; Enzyme Inhibitors; Febuxostat; Female; Hematologic Neoplasms; Humans; Induction Chemotherapy; Japan; Male; Retrospective Studies; Risk Factors; Treatment Outcome; Tumor Lysis Syndrome; Uric Acid; Xanthine Oxidase | 2017 |
Evaluation of the Effectiveness of Xanthine Oxidoreductase Inhibitors on Haemodialysis Patients using a Marginal Structural Model.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Incidence; Kidney Failure, Chronic; Male; Models, Structural; Prognosis; Renal Dialysis; Risk Factors; Survival Rate; Uric Acid; Xanthine Dehydrogenase | 2017 |
Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner.
Topics: Adenosine Triphosphate; Animals; Aspartate Aminotransferase, Mitochondrial; Cell Line; Encephalomyelitis, Autoimmune, Experimental; Energy Metabolism; Febuxostat; Humans; Mice; Mitochondria; Neurons; Oligonucleotide Array Sequence Analysis; Rotenone; Xanthine Oxidase | 2017 |
Green Electroanalytical Method for Fast Measurement of Xanthine Oxidase Inhibitor Febuxostat.
Topics: Boron; Diamond; Electrochemistry; Electrodes; Enzyme Inhibitors; Febuxostat; Green Chemistry Technology; Oxidation-Reduction; Time Factors; Xanthine Oxidase | 2017 |
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study.
Topics: Aged; Allopurinol; Benzbromarone; Cohort Studies; Disease Progression; Drug Monitoring; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Incidence; Male; Middle Aged; Renal Insufficiency, Chronic; Taiwan; Uric Acid; Uricosuric Agents | 2018 |
Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with Adenine phosphoribosyltransferase deficiency (APRTd): A clinical trial.
Topics: Adenine; Adenine Phosphoribosyltransferase; Adult; Aged; Allopurinol; Cross-Over Studies; Enzyme Inhibitors; Febuxostat; Female; Humans; Iceland; Kidney Calculi; Male; Metabolism, Inborn Errors; Middle Aged; Pilot Projects; Registries; Treatment Outcome; Urolithiasis | 2018 |
Efficacy and Safety of Febuxostat in Kidney Transplant Patients.
Topics: Adult; Aged; Biomarkers; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Medical Records; Middle Aged; Retrospective Studies; Risk Factors; Seoul; Treatment Outcome; Uric Acid; Xanthine Oxidase; Young Adult | 2018 |
Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
Topics: Allopurinol; Clinical Trials as Topic; Febuxostat; Humans; Hyperuricemia; Models, Theoretical; Precision Medicine; Thioglycolates; Triazoles; Uric Acid; Uricosuric Agents | 2018 |
Any sleep is a dream far away: a nominal group study assessing how gout affects sleep.
Topics: Aged; Allopurinol; Anxiety; Depression; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Sleep; Sleep Wake Disorders | 2018 |
Chronic Disease Approaches Needed to Curb Gout's Growing Burden.
Topics: Allopurinol; Chronic Disease; Diet; Drug Combinations; Febuxostat; Gout; Gout Suppressants; Healthy Lifestyle; Humans; Patient Education as Topic; Practice Guidelines as Topic; Purines; Thioglycolates; Triazoles; Uric Acid | 2018 |
Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
Topics: Allopurinol; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Thioglycolates; Triazoles | 2018 |
A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China.
Topics: Adult; Allopurinol; China; Cost-Benefit Analysis; Febuxostat; Female; Gene Frequency; Genetic Testing; Gout; Gout Suppressants; HLA-B Antigens; Humans; Hyperuricemia; Male; Middle Aged; Precision Medicine; Retrospective Studies; Treatment Outcome | 2018 |
The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
Topics: Adult; Aged; Allopurinol; Blood Pressure; Febuxostat; Female; Glomerular Filtration Rate; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid | 2018 |
Surprising safety outcomes of urate-lowering therapy.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Uric Acid | 2018 |
A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
Topics: Adult; Aged; Allopurinol; Benzbromarone; Febuxostat; Female; General Practitioners; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Medication Adherence; Middle Aged; Netherlands; Retrospective Studies; Rheumatologists; Uricosuric Agents; Young Adult | 2018 |
Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Biomarkers; Down-Regulation; Drug Resistance; Drug Substitution; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Odds Ratio; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Uric Acid; Young Adult | 2018 |
New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
Topics: Allopurinol; Cardiovascular Diseases; Comorbidity; Enzyme Inhibitors; Europe; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Mortality; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Xanthine Oxidase | 2018 |
Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patients.
Topics: Adult; Aged; Body Weight; Comorbidity; Datasets as Topic; Diabetes Mellitus; Dose-Response Relationship, Drug; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Models, Biological; Sodium Potassium Chloride Symporter Inhibitors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2018 |
[Design, synthesis and biological evaluation of oxadiazole derivatives as xanthine oxidase inhibitors].
Topics: Drug Design; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Oxadiazoles; Xanthine Oxidase | 2016 |
Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Cause of Death; Databases, Factual; Febuxostat; Female; Gout; Hospitalization; Humans; Hyperuricemia; Male; Medicare; Protective Factors; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2018 |
Identification of new drug-like compounds from millets as Xanthine oxidoreductase inhibitors for treatment of Hyperuricemia: A molecular docking and simulation study.
Topics: Allopurinol; Enzyme Inhibitors; Febuxostat; Humans; Hydrogen Bonding; Hyperuricemia; Ligands; Luteolin; Millets; Molecular Docking Simulation; Molecular Dynamics Simulation; Principal Component Analysis; Quercetin; Xanthine Dehydrogenase | 2018 |
Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Dementia; Dose-Response Relationship, Drug; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Incidence; Male; Propensity Score; Proportional Hazards Models; Retrospective Studies | 2018 |
Goals of gout treatment: a patient perspective.
Topics: Allopurinol; Febuxostat; Female; Goals; Gout; Gout Suppressants; Humans; Life Style; Male; Middle Aged; Patient Education as Topic; Symptom Flare Up | 2018 |
Antiremodeling Effect of Xanthine Oxidase Inhibition in a Canine Model of Atrial Fibrillation.
Topics: Animals; Antioxidants; Atrial Fibrillation; Atrial Remodeling; Disease Models, Animal; Dogs; Echocardiography; Febuxostat; Female; Fibronectins; Fibrosis; Gout Suppressants; Heart Atria; Hemodynamics; Oxidative Stress; Reactive Oxygen Species; Xanthine Oxidase | 2018 |
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Topics: Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Probenecid; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Severity of Illness Index; Uric Acid; Uricosuric Agents | 2018 |
Xanthine Oxidase Inhibitor, Febuxostat Ameliorates the High Salt Intake-Induced Cardiac Hypertrophy and Fibrosis in Dahl Salt-Sensitive Rats.
Topics: Animals; Collagen; Disease Models, Animal; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Febuxostat; Fibrosis; Heart Ventricles; Hypertrophy, Left Ventricular; Male; NADPH Oxidases; Phosphorylation; Rats, Inbred Dahl; Reactive Oxygen Species; Renin-Angiotensin System; Sodium Chloride, Dietary; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling; Xanthine Oxidase | 2019 |
Fresh Perspectives on the CARES Trial and the Use of Febuxostat in an Asian Population: Comment on the Article by Choi et al.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; United States Food and Drug Administration | 2019 |
Febuxostat Does Not Increase All-Cause Mortality and Cardiovascular Mortality Compared With Placebo: Comment on the Article by Choi et al.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; United States Food and Drug Administration | 2019 |
Reply.
Topics: Allopurinol; Febuxostat; Gout; Humans; Rheumatology; United States; United States Food and Drug Administration | 2019 |
Xanthine Oxidase Inhibition by Febuxostat in Macrophages Suppresses Angiotensin II-Induced Aortic Fibrosis.
Topics: Actins; Adventitia; Angiotensin II; Animals; Aorta; Aortic Diseases; Disease Models, Animal; Febuxostat; Fibroblasts; Fibrosis; Gout Suppressants; Hypertension; Macrophages; Male; Mice, Inbred C57BL; Transforming Growth Factor beta1; Vascular Remodeling; Xanthine Oxidase | 2019 |
Gout, Xanthine Oxidase Inhibition, and Cardiovascular Outcomes.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Risk Factors; Xanthine Oxidase | 2018 |
Prescribing patterns of allopurinol and febuxostat according to directives on the reimbursement criteria and clinical guidelines: analysis of a primary care database.
Topics: Allopurinol; Databases, Factual; Febuxostat; Humans; Hyperuricemia; Practice Guidelines as Topic; Practice Patterns, Physicians'; Primary Health Care; Reimbursement Mechanisms; Retrospective Studies | 2019 |
Nitrite treatment downregulates vascular MMP-2 activity and inhibits vascular remodeling in hypertension independently of its antihypertensive effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Aorta; Blood Pressure; Disease Models, Animal; Febuxostat; Gene Expression Regulation; Humans; Hypertension, Renovascular; Matrix Metalloproteinase 2; Muscle, Smooth, Vascular; Nitric Oxide; Nitrites; Oxidative Stress; Rats; Reactive Oxygen Species; Vascular Remodeling; Xanthine Oxidase | 2019 |
Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease.
Topics: Adult; Allopurinol; Analysis of Variance; Cohort Studies; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Liver; Febuxostat; Female; Gout; Gout Suppressants; Humans; Liver; Liver Function Tests; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Doppler | 2019 |
Impact of Non-Adherence and Flare Resolution on the Cost-Effectiveness of Treatments for Gout: Application of a Linked Pharmacometric/Pharmacoeconomic Model.
Topics: Allopurinol; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Febuxostat; Gout; Gout Suppressants; Health Care Costs; Humans; Medication Adherence; Models, Biological; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Thioglycolates; Treatment Outcome; Triazoles; United Kingdom; Uric Acid | 2018 |
Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation.
Topics: Allopurinol; Cardiovascular Diseases; Cause of Death; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Randomized Controlled Trials as Topic; Risk Factors | 2019 |
The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model.
Topics: Animals; Anti-Inflammatory Agents; Chemokines; Disease Progression; Endoplasmic Reticulum Stress; Febuxostat; Female; Fibrosis; Gene Expression Regulation; Glomerulonephritis, IGA; Inflammation Mediators; Kidney; Mice, Inbred BALB C; Xanthine Oxidase | 2018 |
Gout and the risk of incident depression in older adults.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Comorbidity; Depressive Disorder; Febuxostat; Female; Follow-Up Studies; Gout; Humans; Incidence; Male; Mass Screening; Medicare; Proportional Hazards Models; Retrospective Studies; Risk; United States | 2018 |
Xanthine Oxidase Inhibition as a Potential Treatment for Aortic Stiffness in Hypertension.
Topics: Angiotensin II; Febuxostat; Fibrosis; Humans; Hypertension; Macrophages; Vascular Stiffness; Xanthine Oxidase | 2019 |
Efficacy of the HLA-B
Topics: Aged; Allergens; Allopurinol; Drug Hypersensitivity; Febuxostat; Female; Genotype; Histocompatibility Testing; HLA-B Antigens; Humans; Korea; Male; Mass Screening; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Risk; Skin | 2019 |
Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
Topics: Adolescent; Adult; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney Transplantation; Male; Middle Aged; Retrospective Studies; Time Factors; Transplant Recipients; Treatment Outcome; Uric Acid; Young Adult | 2019 |
Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Topics: Aged; Allopurinol; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Time Factors; Uric Acid | 2019 |
A novel voltammetry offline coupled MALDI/TOF MS characterization of electrochemical reaction products and the voltammetric determination of febuxostat in human plasma.
Topics: Blood Chemical Analysis; Carboxylic Acids; Electrochemistry; Febuxostat; Humans; Nitriles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Xanthine Oxidase | 2019 |
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Nutrition Surveys; Prevalence; Probenecid; United States; Uric Acid; Uricosuric Agents; Young Adult | 2019 |
Discovery of 2-phenylthiazole-4-carboxylic acid, a novel and potent scaffold as xanthine oxidase inhibitors.
Topics: Drug Discovery; Enzyme Inhibitors; Febuxostat; Thiazolidines; Xanthine Oxidase | 2019 |
Limitations in Assessing Cardiovascular Risk of Febuxostat in Patients With Gout and Cardiovascular Morbidities: Comment on the Article by Choi et al.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; Risk Factors; United States Food and Drug Administration | 2019 |
Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: A nationwide study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Child; Child, Preschool; Cohort Studies; Drug Eruptions; Febuxostat; Female; Gout; Gout Suppressants; Humans; Infant; Infant, Newborn; Interrupted Time Series Analysis; Male; Middle Aged; Retrospective Studies; Risk Factors; Taiwan; Young Adult | 2019 |
Protective effects of febuxostat against paraquat-induced lung toxicity in rats: Impact on RAGE/PI3K/Akt pathway and downstream inflammatory cascades.
Topics: Acute Lung Injury; Animals; beta Catenin; Febuxostat; Inflammation; Lung; Lung Injury; Male; Oxidative Stress; Paraquat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pulmonary Edema; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Xanthine Oxidase | 2019 |
Letter by Kuwabara Regarding Article, "Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study".
Topics: Aged; Allopurinol; Cardiovascular Diseases; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Patients; Population; Risk Factors | 2019 |
Dual inhibition of NADPH oxidases and xanthine oxidase potently prevents salt-induced stroke in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Antioxidants; Blood Pressure; Cyclic N-Oxides; Enzyme Inhibitors; Febuxostat; Male; NADPH Oxidases; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Transgenic; Reactive Oxygen Species; Sodium Chloride; Spin Labels; Stroke; Ubiquinone; Xanthine Oxidase | 2019 |
Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients.
Topics: Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout Suppressants; Heart Failure; Humans; Hyperuricemia; Male; Middle Aged | 2019 |
Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update.
Topics: Aged; Allopurinol; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Uric Acid; Xanthine Oxidase | 2019 |
The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients.
Topics: Adolescent; Adult; Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; Child; Child, Preschool; Cohort Studies; Czech Republic; Febuxostat; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Young Adult | 2019 |
Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data.
Topics: Aged; Allopurinol; Atrial Fibrillation; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Medicare; United States | 2019 |
Gout and chronic pain in older adults: a Medicare claims study.
Topics: Aged; Aged, 80 and over; Allopurinol; Chronic Pain; Comorbidity; Febuxostat; Female; Gout; Humans; Incidence; Male; Medicare; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; United States | 2019 |
The difficult relationship between uric acid and cardiovascular disease.
Topics: Aged; Allopurinol; Atrial Fibrillation; Cardiovascular Diseases; Febuxostat; Humans; Medicare; Risk Factors; United States; Uric Acid | 2019 |
Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Renal Insufficiency, Chronic; Republic of Korea; Treatment Outcome; Uric Acid | 2020 |
Integration of Pharmacometrics and Pharmacoeconomics to Quantify the Value of Improved Forgiveness to Nonadherence: A Case Study of Novel Xanthine Oxidase Inhibitors for Gout.
Topics: Allopurinol; Computer Simulation; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Monitoring; Economics, Pharmaceutical; Febuxostat; Gout; Gout Suppressants; Humans; Insurance, Health, Reimbursement; Medication Adherence; Quality-Adjusted Life Years; Uric Acid; Xanthine Oxidase | 2019 |
Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment-Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; United States Food and Drug Administration; Xanthine Oxidase | 2019 |
Xanthine oxidase inhibitors in elderly patients with heart failure: useful or useless?
Topics: Aged; Allopurinol; Enzyme Inhibitors; Febuxostat; Heart Failure; Humans; Xanthine Oxidase | 2019 |
Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Republic of Korea; Stroke | 2019 |
A novel strategy for treatment of cancer cachexia targeting xanthine oxidase in the brain.
Topics: Administration, Oral; Animals; Brain; Cachexia; Disease Models, Animal; Febuxostat; Male; Mice, Inbred BALB C; Neoplasms; Purines; Xanthine Oxidase | 2019 |
Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients.
Topics: Adult; Allografts; Allopurinol; Drug Substitution; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Kidney Transplantation; Male; Middle Aged; Transplant Recipients; Treatment Outcome; Uric Acid | 2019 |
Cardiovascular Safety of Febuxostat Versus Allopurinol in the Real World: Old Reliable Comes Out on Top.
Topics: Allopurinol; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans | 2019 |
Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Databases, Factual; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Male; Retrospective Studies; Risk Factors; Taiwan | 2019 |
Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
Topics: Adult; Allopurinol; Benzbromarone; Biomarkers; Cholesterol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Triglycerides; Uric Acid; Uricosuric Agents | 2019 |
Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.
Topics: Aged; Alcohol Drinking; Allopurinol; Benzbromarone; Diet Therapy; Febuxostat; Female; Foot Joints; Fructose; Gout; Gout Suppressants; Humans; Male; Meat; Middle Aged; Prospective Studies; Purines; Shellfish; Tomography, X-Ray Computed; Uric Acid; Uricosuric Agents | 2020 |
Xanthine Oxidase Inhibitor Withdrawal Syndrome? Comment on the Article by Choi et al.
Topics: Allopurinol; Febuxostat; Gout; Humans; Rheumatology; United States; United States Food and Drug Administration; Xanthine Oxidase | 2019 |
Reply.
Topics: Allopurinol; Febuxostat; Gout; Humans; Rheumatology; United States; United States Food and Drug Administration | 2019 |
Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
Topics: Allopurinol; Cost-Benefit Analysis; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Markov Chains; Spain; Thioglycolates; Triazoles | 2019 |
Evaluation of Treatment Success Rate Among Antihyperuricemic Using Real-World Data.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2019 |
Febuxostat attenuates ulcerative colitis by the inhibition of NF-κB, proinflammatory cytokines, and oxidative stress in mice.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents; Antioxidants; Colitis, Ulcerative; Colon; Cytokines; Febuxostat; Glutathione; Male; Malondialdehyde; Mice, Inbred BALB C; NF-kappa B; Nitric Oxide; Oxidative Stress; Peroxidase; Superoxide Dismutase; Xanthine Oxidase | 2019 |
Rising Incidence of Acute Hospital Admissions due to Gout.
Topics: Adult; Allopurinol; Febuxostat; Gout; Gout Suppressants; Hospitals; Humans; Incidence; State Medicine | 2020 |
Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.
Topics: Allopurinol; Benzbromarone; Disease Progression; Febuxostat; Female; Glomerular Filtration Rate; Gout; Gout Suppressants; Humans; Incidence; Male; Middle Aged; Recovery of Function; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid; Uricosuric Agents | 2019 |
Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemokine CCL2; Collagen; Diabetic Nephropathies; Febuxostat; Glucose Intolerance; Hyperglycemia; Hyperuricemia; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-6; Kidney Glomerulus; Mice; Mice, Inbred C57BL; Mice, Obese; Oxidative Stress; Peptide Fragments; Uric Acid; Xanthine Oxidase | 2019 |
Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Databases, Factual; Disease Progression; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Taiwan; Young Adult | 2020 |
Purine versus non-purine xanthine oxidase inhibitors against cyclophosphamide-induced cardiac and bone marrow toxicity in rats.
Topics: Allopurinol; Animals; Bone Marrow; Creatine Kinase, MB Form; Cyclophosphamide; Enzyme Inhibitors; Febuxostat; Gout Suppressants; Heart Diseases; Immunosuppressive Agents; L-Lactate Dehydrogenase; Male; Rats; Rats, Wistar; Xanthine Oxidase | 2020 |
Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
Topics: Aged; Allopurinol; Disease Progression; Febuxostat; Female; Humans; Hyperuricemia; Kidney; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Treatment Outcome | 2019 |
Role of allopurinol and febuxostat in the amelioration of dextran-induced colitis in rats.
Topics: Allopurinol; Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Colon; Dextran Sulfate; Drug Therapy, Combination; Febuxostat; Glutathione; Interleukin-1beta; Interleukin-6; Male; Malondialdehyde; Rats, Wistar; Sulfasalazine; Superoxide Dismutase; Uric Acid; Xanthine Oxidase | 2020 |
Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
Topics: Adult; Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Uric Acid | 2020 |
Febuxostat, a novel inhibitor of xanthine oxidase, reduces ER stress through upregulation of SIRT1-AMPK-HO-1/thioredoxin expression.
Topics: AMP-Activated Protein Kinases; Animals; Benzamides; Cell Line; Drug Evaluation, Preclinical; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Febuxostat; Heme Oxygenase-1; Humans; Mice; Naphthols; Renal Insufficiency, Chronic; Signal Transduction; Sirtuin 1; Thioredoxins; Tunicamycin; Xanthine Oxidase | 2020 |
Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study.
Topics: Acute Kidney Injury; Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Pharmacovigilance; Product Surveillance, Postmarketing; Treatment Outcome | 2019 |
Xanthine oxidase inhibitor ameliorates postischemic renal injury in mice by promoting resynthesis of adenine nucleotides.
Topics: Acute Kidney Injury; Adenine Nucleotides; Animals; Enzyme Inhibitors; Febuxostat; Kidney; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Reactive Oxygen Species; Reperfusion Injury; Xanthine Oxidase | 2019 |
Discontinuing febuxostat might cause more deaths than continuing febuxostat: the untold story from the CARES trial.
Topics: Adult; Allopurinol; Cardiovascular Diseases; Cause of Death; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome; Withholding Treatment | 2020 |
Burden and management of gout in a multi-ethnic Asian cohort.
Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Emergency Service, Hospital; Ethnicity; Febuxostat; Female; Gout; Gout Suppressants; Hospitalization; Humans; Hypertension; Hyperuricemia; Male; Middle Aged; Probenecid; Renal Insufficiency, Chronic; Severity of Illness Index; Singapore; Treatment Outcome; Uric Acid | 2020 |
A word of caution regarding Febuxostat.
Topics: Allopurinol; Cardiovascular Diseases; Drug-Related Side Effects and Adverse Reactions; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Pakistan; Xanthine Oxidase | 2019 |
Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
Topics: Aged; Aged, 80 and over; Allopurinol; Cardiovascular Diseases; Enzyme Inhibitors; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Male; Middle Aged; Retrospective Studies; Xanthine Oxidase | 2020 |
Kidney Transplant Outcomes in Patients With Adenine Phosphoribosyltransferase Deficiency.
Topics: Adenine Phosphoribosyltransferase; Adolescent; Adult; Aged; Allopurinol; Enzyme Inhibitors; Europe; Febuxostat; Female; Graft Survival; Humans; India; Kidney Failure, Chronic; Kidney Transplantation; Male; Metabolism, Inborn Errors; Middle Aged; New South Wales; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; United States; Urolithiasis; Xanthine Oxidase; Young Adult | 2020 |
Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Topics: Allopurinol; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Febuxostat; Hyperuricemia; Insulin Resistance; Lipid Peroxidation; Liver; Macrophage Activation; Mice, Inbred C57BL; Molecular Targeted Therapy; Uric Acid; Xanthine Oxidase | 2020 |
Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data.
Topics: Age Factors; Aged; Aged, 80 and over; Allopurinol; Colchicine; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Therapy, Combination; Febuxostat; Female; Gout Suppressants; Humans; Incidence; Male; Medicare; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Sex Factors; United States | 2020 |
Efficacy and tolerability of febuxostat in gout patients on dialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Retrospective Studies; Treatment Outcome; Uric Acid | 2021 |
Protective effect of febuxostat in sepsis-induced liver and kidney injuries after cecal ligation and puncture with the impact of xanthine oxidase, interleukin 1
Topics: Acute Kidney Injury; Alanine Transaminase; Animals; Aspartate Aminotransferases; Cecum; Creatinine; Febuxostat; Interleukin-1beta; JNK Mitogen-Activated Protein Kinases; Kidney; Ligation; Liver; Liver Diseases; Male; Protective Agents; Rats, Wistar; Sepsis; Urea; Xanthine Oxidase | 2020 |
[Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Morbidity | 2020 |
Febuxostat and atrial fibrillation.
Topics: Aged; Allopurinol; Atrial Fibrillation; Febuxostat; Gout; Gout Suppressants; Humans; Medicare; United States | 2020 |
PTEN/PI3K/VEGF signaling pathway involved in the protective effect of xanthine oxidase inhibitor febuxostat against endometrial hyperplasia in rats.
Topics: Animals; Endometrial Hyperplasia; Enzyme Inhibitors; Estradiol; Febuxostat; Female; Oxidative Stress; Phosphatidylinositol 3-Kinase; PTEN Phosphohydrolase; Rats; Rats, Wistar; Signal Transduction; Vascular Endothelial Growth Factor A; Xanthine Oxidase | 2020 |
Febuxostat Promoted Dissolution of Radiolucent Nephrolithiasis in Patients with Hyperuricemia.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Nephrolithiasis; Retrospective Studies; Young Adult | 2020 |
High Salt Intake-Increased (Pro)renin Receptor Expression Is Exaggerated in the Kidney of Dahl Salt-Sensitive Rats.
Topics: Animals; Blood Pressure; Febuxostat; Flavoring Agents; Gene Expression Regulation; Hypertension; Mineralocorticoid Receptor Antagonists; Nephrons; Prorenin Receptor; Rats; Rats, Inbred Dahl; Receptors, Cell Surface; Renin-Angiotensin System; Sodium Chloride, Dietary; Spironolactone; Xanthine Oxidase | 2020 |
2020 American College of Rheumatology Guideline for the Management of Gout.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Rheumatology; United States | 2020 |
Inhibition of xanthine oxidase in the acute phase of myocardial infarction prevents skeletal muscle abnormalities and exercise intolerance.
Topics: Animals; Cell Hypoxia; Cell Line; Disease Models, Animal; Enzyme Inhibitors; Exercise Tolerance; Febuxostat; Male; Mice, Inbred C57BL; Mitochondria, Muscle; Muscle Fibers, Skeletal; Muscle Strength; Muscle, Skeletal; Muscular Atrophy; Myocardial Infarction; Reactive Oxygen Species; Ribosomal Protein S6 Kinases, 70-kDa; Time Factors; TOR Serine-Threonine Kinases; Xanthine Oxidase | 2021 |
Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Middle Aged; Retrospective Studies; Uric Acid | 2020 |
Underscoring the Importance of Allopurinol in Treating Gout: Results of a Food and Drug Administration-Mandated Safety Trial.
Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2020 |
Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Febuxostat; Heart; Hyperuricemia; Kidney Diseases; Kidney Function Tests; Male; Myocardium; Nephrectomy; Oxidative Stress; Oxonic Acid; Protective Agents; Rats, Sprague-Dawley; Xanthine Oxidase | 2020 |
Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma
Topics: Aged; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States | 2022 |
Confounding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
Topics: Aged; Allopurinol; Ethnicity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States | 2022 |
Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu
Topics: Aged; Allopurinol; Ethnicity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States | 2022 |
Correspondence to 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
Topics: Aged; Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Medicare; United States | 2022 |
[Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
Topics: Allopurinol; Comorbidity; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Prevalence; Uric Acid | 2019 |
Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Topics: Allopurinol; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Retrospective Studies; Thailand; Thiazoles; Treatment Outcome; Uric Acid | 2021 |
Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Allopurinol; Cohort Studies; Febuxostat; Female; Follow-Up Studies; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Taiwan; Uric Acid | 2020 |
Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia | 2022 |
Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Skin | 2022 |
Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation | 2020 |
In older adults, new use of allopurinol or febuxostat was linked to hypersensitivity reactions versus colchicine.
Topics: Aged; Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Medicare; United States | 2020 |
Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
Topics: Adult; Aged; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Philippines; Treatment Outcome; Uric Acid | 2021 |
Comparison of the Effects of Allopurinol and Febuxostat on the Values of Triglycerides in Hyperuricemic Patients.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Prospective Studies; Retrospective Studies; Time Factors; Triglycerides; Uric Acid | 2020 |
Trends in Utilization of Urate-Lowering Therapies Following the US Food and Drug Administration's Boxed Warning on Febuxostat.
Topics: Allopurinol; Cardiovascular Diseases; Cause of Death; Drug Labeling; Febuxostat; Gout; Gout Suppressants; Humans; Mortality; Polyethylene Glycols; Practice Patterns, Physicians'; Probenecid; Risk Factors; Thioglycolates; Triazoles; United States; United States Food and Drug Administration; Urate Oxidase | 2021 |
Febuxostat Attenuates the Induction of Vascular Cell Adhesion Protein 1 by TNF-α in Human Umbilical Vein Endothelial Cells.
Topics: Allopurinol; Anti-Inflammatory Agents; Cells, Cultured; Febuxostat; Human Umbilical Vein Endothelial Cells; Humans; I-kappa B Proteins; NF-kappa B p50 Subunit; Protein Transport; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2021 |
FAST: new look at the febuxostat safety profile.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Prospective Studies | 2020 |
Febuxostat cardiovascular safety revisited.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Prospective Studies | 2021 |
Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Animals; Disease Models, Animal; Enzyme Inhibitors; Erythrocytes; Febuxostat; Hemodynamics; Hemolysis; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Pulmonary Artery; Ventricular Function; Xanthine Oxidase | 2021 |
Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design.
Topics: Allopurinol; Bayes Theorem; Clinical Trials, Phase III as Topic; Computer Simulation; Decision Theory; Drug Development; Economics, Pharmaceutical; Febuxostat; Gout; Humans; Hyperuricemia; Investments; Models, Biological; Models, Economic; Reimbursement Mechanisms; Research Design; Sample Size; Uncertainty; Uric Acid | 2021 |
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Endothelial Cells; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Japan; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk Factors; Uric Acid | 2021 |
Effects of the xanthine oxidase inhibitor, febuxostat, on the expression of monocyte chemoattractant protein-1 and synchronous genes in MDCK cells treated with calcium oxalate monohydrate crystals.
Topics: Animals; Calcium Oxalate; Chemokine CCL2; Dogs; Febuxostat; Kidney; Madin Darby Canine Kidney Cells; Xanthine Oxidase | 2021 |
Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans | 2021 |
Xanthine oxidase inhibition attenuates doxorubicin-induced cardiotoxicity in mice.
Topics: Animals; Cardiotoxicity; Doxorubicin; Febuxostat; Mice; Uric Acid; Xanthine Oxidase | 2021 |
Safety profiles of new xanthine oxidase inhibitors: A post-marketing study.
Topics: Allopurinol; Febuxostat; Humans; Male; Marketing; Retrospective Studies; Xanthine Oxidase | 2021 |
Inosine induces acute hyperuricaemia in rhesus monkey (
Topics: Acute Disease; Allopurinol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Febuxostat; Hyperuricemia; Imino Furanoses; Inosine; Macaca mulatta; Male; Pyrimidinones; Reproducibility of Results; Uric Acid | 2021 |
Is Febuxostat Use Associated With Increased Risk of Cardiovascular Disease Events? The Answer Is Crystal Clear.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout Suppressants; Humans | 2021 |
Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol.
Topics: Aged; Allopurinol; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Humans; Incidence; Male; Retrospective Studies; Risk Assessment; Survival Rate; United States | 2021 |
Comparative efficacy of low-dose versus regular-dose colchicine to prevent flares in gout patients initiated on urate-lowering therapies.
Topics: Adult; Aged; Allopurinol; Cohort Studies; Colchicine; Drug Therapy, Combination; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Symptom Flare Up | 2021 |
Drastic monosodium urate crystal dissolution with febuxostat and benzbromarone.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Solubility; Uric Acid | 2021 |
[Cardiovascular risk in gout - Role of allopurinol?]
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Male; Risk Factors | 2021 |
Comparing the Effects of Febuxostat and Allopurinol in an Animal Model of Metabolic Syndrome.
Topics: Allopurinol; Animals; Blood Glucose; Blood Pressure; Body Weight; Catalase; Disease Models, Animal; Febuxostat; Glutathione Peroxidase; Insulin Resistance; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Xanthine Oxidase | 2021 |
Accurate quantitative determination of affinity and binding kinetics for tight binding inhibition of xanthine oxidase.
Topics: Cells, Cultured; Enzyme Inhibitors; Febuxostat; Humans; Kinetics; Protein Binding; Structure-Activity Relationship; Xanthine Oxidase | 2021 |
Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats.
Topics: Allopurinol; Animals; Atrial Fibrillation; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Connexins; Disease Models, Animal; Enzyme Inhibitors; Febuxostat; Fibrosis; Gap Junction alpha-5 Protein; Gap Junctions; Hypertension; Male; Myocytes, Cardiac; Oxidation-Reduction; Phosphorylation; Rats, Inbred Dahl; Ryanodine Receptor Calcium Release Channel; Sodium Chloride, Dietary; Xanthine Oxidase | 2021 |
Investigation of the interaction between Chrysoeriol and xanthine oxidase using computational and in vitro approaches.
Topics: Allopurinol; Animals; Calorimetry; Cattle; Circular Dichroism; Computational Biology; Enzyme Inhibitors; Febuxostat; Flavones; Fluorescent Dyes; Hemolysis; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Structure, Secondary; Rabbits; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Time Factors; Xanthine Oxidase | 2021 |
Incorporating gout guideline advice into urate reports is associated with reduced hospital admissions: results of an observational study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Hospitals; Humans; Treatment Outcome; Uric Acid | 2022 |
Febuxostat, an inhibitor of xanthine oxidase, ameliorates ionizing radiation-induced lung injury by suppressing caspase-3, oxidative stress and NF-κB.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Caspase 3; Febuxostat; Inflammation; Lung Injury; Mice; NF-kappa B; Oxidative Stress; Radiation, Ionizing; Xanthine Oxidase | 2022 |
Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat.
Topics: Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Febuxostat; Female; Gout Suppressants; Humans; Methotrexate; Middle Aged; Neoplasm Proteins | 2022 |
Clinical characteristics of juvenile gout and treatment response to febuxostat.
Topics: Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Kidney Diseases; Male; Treatment Outcome | 2022 |
Treating gout - can hypouricemia produced by moderate doses of combined oral treatment give early treatment success? Preliminary observations.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Male; Treatment Outcome; Uric Acid | 2022 |
Exploring the binding characteristics of febuxostat, an inhibitor of xanthine oxidase with calf thymus DNA: Multi-spectroscopic methodologies and molecular docking.
Topics: Circular Dichroism; DNA; Febuxostat; Humans; Molecular Docking Simulation; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thermodynamics; Xanthine Oxidase | 2022 |
Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
Topics: Aged; Allopurinol; Austria; Cardiovascular Diseases; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Hyperuricemia; Ischemic Stroke; Male; Retrospective Studies; Risk Factors; Uric Acid | 2022 |
Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia | 2022 |
Reply to comment on "Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis".
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans | 2022 |
Febuxostat Use and Safety in Patients With Hyperuricemia.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome | 2022 |
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial.
Topics: Allopurinol; Cardiovascular Diseases; Clinical Trials as Topic; Febuxostat; Gout; Gout Suppressants; Humans | 2022 |
POSSIBILITIES OF RENOPROTECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERURICEMIA.
Topics: Allopurinol; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2022 |
Febuxostat Increases Ventricular Arrhythmogenesis Through Calcium Handling Dysregulation in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Topics: Allopurinol; Arrhythmias, Cardiac; Calcium; Extracellular Signal-Regulated MAP Kinases; Febuxostat; Humans; Induced Pluripotent Stem Cells; JNK Mitogen-Activated Protein Kinases; Myocytes, Cardiac; Uric Acid; Xanthine Oxidase | 2022 |
Inhibition of Xanthine Oxidase Protects against Sepsis-Induced Acute Kidney Injury by Ameliorating Renal Hypoxia.
Topics: Acute Kidney Injury; Animals; Febuxostat; Hypoxia; Inflammation; Ischemia; Kidney; Lipopolysaccharides; Mice; Oxygen; Reactive Oxygen Species; RNA, Small Interfering; Sepsis; Xanthine Oxidase | 2022 |
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
Topics: Adipocytes; Allopurinol; Colchicine; Enzyme Inhibitors; Fatty Acids, Nonesterified; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Lipolysis; Prospective Studies; Uric Acid; Xanthine Oxidase | 2022 |
Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2022 |
Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.
Topics: Allopurinol; Cohort Studies; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hyperuricemia; Male; Middle Aged; Myocardial Infarction; Treatment Outcome | 2022 |
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans | 2022 |
Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection.
Topics: Allopurinol; Animals; Antitubercular Agents; Febuxostat; Mice; Mycobacterium tuberculosis; Tuberculosis | 2022 |
A modified xanthine oxidase cell model for screening of antihyperuricemic functional compounds.
Topics: Adenosine; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Hypoxanthines; Peptides; Uric Acid; Xanthine Oxidase | 2022 |
Discovery of novel 1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors with hypouricemic effects.
Topics: Animals; Enzyme Inhibitors; Febuxostat; Gout; Hyperuricemia; Mice; Triazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2022 |
Febuxostat, a potential drug in the secondary prevention of cardiovascular disease with hyperuricemia.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Secondary Prevention; Treatment Outcome | 2023 |
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Insurance, Health; Japan; Risk Factors; Treatment Outcome; Uric Acid | 2023 |
A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout.
Topics: Adult; Aged; Allopurinol; Arthritis, Gouty; Febuxostat; Female; Gout; Gout Suppressants; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Uric Acid | 2023 |
`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea.
Topics: Allopurinol; Cardiovascular Diseases; Cohort Studies; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Republic of Korea; Retrospective Studies | 2023 |
Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study.
Topics: Adult; Allopurinol; Cohort Studies; Erectile Dysfunction; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Male | 2022 |
Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Interrupted Time Series Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Retrospective Studies; Taiwan | 2023 |
Xanthine oxidase mediates chronic stress-induced cerebrovascular dysfunction and cognitive impairment.
Topics: Animals; Cardiovascular Physiological Phenomena; Cerebrovascular Circulation; Cerebrovascular Disorders; Cognitive Dysfunction; Enzyme Inhibitors; Febuxostat; Free Radicals; Hydrogen Peroxide; Memory, Short-Term; Mice; Mice, Inbred C57BL; Stress, Psychological; Xanthine Oxidase | 2023 |
Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients.
Topics: Allopurinol; Colchicine; Febuxostat; Gout; Gout Suppressants; Humans; Male; Prevalence; Quality of Life; Renal Dialysis | 2023 |
A lifetime economic research of universal HLA-B*58:01 genotyping or febuxostat initiation therapy in Chinese gout patients with mild to moderate chronic kidney disease.
Topics: Allopurinol; China; Cost-Benefit Analysis; East Asian People; Febuxostat; Gout; Gout Suppressants; HLA-B Antigens; Humans; Quality-Adjusted Life Years; Renal Insufficiency, Chronic | 2023 |
Inhibition of Xanthine Oxidase Protects against Diabetic Kidney Disease through the Amelioration of Oxidative Stress via VEGF/VEGFR Axis and NOX-FoxO3a-eNOS Signaling Pathway.
Topics: Animals; Diabetic Nephropathies; Endothelial Cells; Febuxostat; Humans; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; RNA, Messenger; Signal Transduction; Uric Acid; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xanthine Oxidase | 2023 |
Superiority of low-dose benzbromarone to low-dose febuxostat in gout patients with renal uric acid underexcretion: comment on the article by Yan et al.
Topics: Allopurinol; Benzbromarone; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Treatment Outcome; Uric Acid | 2023 |
Comparison between the Effects of Allopurinol and Febuxostat on the Survival of Patients on Maintenance Hemodialysis.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Renal Dialysis; Treatment Outcome; Uric Acid | 2023 |
Safety update: febuxostat and CVD.
Topics: Allopurinol; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Humans; Treatment Outcome; Uric Acid | 2023 |
Antioxidant action of xanthine oxidase inhibitor febuxostat protects the liver and blood vasculature in SHRSP5/Dmcr rats.
Topics: Animals; Antioxidants; Atherosclerosis; Diet, High-Fat; Enzyme Inhibitors; Febuxostat; Lipids; Non-alcoholic Fatty Liver Disease; Rats; Rats, Inbred SHR; Uric Acid; Xanthine Oxidase | 2023 |
Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate-lowering therapy in patients with gout using the Korean Health Insurance Review and Assessment Service database.
Topics: Adult; Allopurinol; Colchicine; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Insurance Claim Review; Insurance, Health; Republic of Korea; Retrospective Studies; Uric Acid; Xanthine Oxidase; Young Adult | 2023 |
Febuxostat, a xanthine oxidase inhibitor, regulated long noncoding RNAs and protected the brain after intracerebral hemorrhage.
Topics: Animals; Brain; Cerebral Hemorrhage; Enzyme Inhibitors; Febuxostat; Mice; RNA, Long Noncoding; Xanthine Oxidase | 2023 |